<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nutr Diabetes</journal-id><journal-id journal-id-type="iso-abbrev">Nutr Diabetes</journal-id><journal-title-group><journal-title>Nutrition &#x00026; Diabetes</journal-title></journal-title-group><issn pub-type="epub">2044-4052</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40393987</article-id><article-id pub-id-type="pmc">PMC12092638</article-id>
<article-id pub-id-type="publisher-id">377</article-id><article-id pub-id-type="doi">10.1038/s41387-025-00377-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>TMAO and diabetes: from the gut feeling to the heart of the problem</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0281-015X</contrib-id><name><surname>Jaworska</surname><given-names>Kinga</given-names></name><address><email>kinga.jaworska@wum.edu.pl</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ku&#x0015b;</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ufnal</surname><given-names>Marcin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04p2y4s44</institution-id><institution-id institution-id-type="GRID">grid.13339.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 1328 7408</institution-id><institution>Department of Experimental Physiology and Pathophysiology, Laboratory of the Centre for Preclinical Research, </institution><institution>Medical University of Warsaw, </institution></institution-wrap>Warsaw, Poland </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>21</elocation-id><history><date date-type="received"><day>7</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>30</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Elevated plasma levels of trimethylamine N-oxide (TMAO)&#x02014;a compound derived from diet and the gut microbiome&#x02014;have been widely studied for their association with diabetes risk and their potential role in disease pathophysiology and complications. However, clinical studies, both prospective and retrospective, have yielded conflicting results. For example, elevated levels of TMAO are frequently linked to an increased risk of cardiovascular and renal complications in individuals with diabetes. However, the robustness and independence of these associations differ across study populations and are influenced by the degree of adjustment for confounding risk factors. Considering insulin&#x02019;s regulatory effect on FMO3 activity in liver cells, TMAO may serve as a marker of hepatic insulin resistance, which could partially explain its association with diabetes risk. The role of TMAO in diabetes pathology remains controversial; while some studies emphasize its detrimental impact on insulin sensitivity and the progression of diabetes-related complications, others suggest potential protective effects. Investigating the largely unexplored role of TMAO&#x02019;s precursor, trimethylamine, may help elucidate these discrepancies. This review consolidates clinical and experimental findings to clarify TMAO&#x02019;s complex mechanistic contributions to diabetes pathology.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Diabetes</kwd><kwd>Preclinical research</kwd><kwd>Risk factors</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100004281</institution-id><institution>Narodowe Centrum Nauki (National Science Centre)</institution></institution-wrap></funding-source><award-id>UMO-2020/37/B/NZ5/00366</award-id><award-id>UMO-2020/37/B/NZ5/00366</award-id><award-id>UMO-2020/37/B/NZ5/00366</award-id><principal-award-recipient><name><surname>Jaworska</surname><given-names>Kinga</given-names></name><name><surname>Ku&#x0015b;</surname><given-names>Monika</given-names></name><name><surname>Ufnal</surname><given-names>Marcin</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">The management of diabetes and its long-term complications has significantly improved over the past decade with the introduction of new therapeutic interventions aimed at optimizing blood glucose control and weight management, such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), alongside the promotion of healthier lifestyle. This has contributed to improved patient outcomes. However, diabetes remains a significant socioeconomic burden due to its rising prevalence. According to the International Diabetes Federation, nearly half a billion people worldwide are currently living with diabetes, and this figure is projected to increase by 51% by 2045 [<xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, continuous efforts are being made to fully uncover the underlying pathophysiological processes and to identify new intervention targets or markers for recognizing high-risk individuals.</p><p id="Par3">Recent research on the role of gut microbiota in health and disease has grown rapidly. Studies have demonstrated associations between gut microbial dysbiosis and type 1 diabetes [<xref ref-type="bibr" rid="CR2">2</xref>], type 2 diabetes [<xref ref-type="bibr" rid="CR3">3</xref>], and insulin sensitivity [<xref ref-type="bibr" rid="CR4">4</xref>]. However, the underlying mechanisms and causal relationships remain to be fully established.</p><p id="Par4">Among the potential mediators of microbiota-host interactions, trimethylamine N-oxide (TMAO), a derivative of bacterial metabolism, has garnered significant scientific interest once it has been linked to increased cardiovascular risk [<xref ref-type="bibr" rid="CR5">5</xref>]. Since then, numerous experimental and clinical studies have explored TMAO&#x02019;s as a marker and mediator of pathological and/or adaptive processes. Similarly, research on the role of TMAO in the risk assessment of diabetic patients and its involvement in the pathological processes of diabetes and its complications is growing [<xref ref-type="bibr" rid="CR6">6</xref>]. However, the data are somewhat conflicting, presenting challenges for the development of new diagnostic, prognostic, or treatment strategies in cardiovascular diseases whether using TMAO as a biomarker or a therapeutic target [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par5">The purpose of this review is to summarize the available evidence on the role of TMAO in diabetes, encompassing both clinical and experimental studies. Relevant studies evaluating the association between TMAO and diabetes were searched in electronic databases up to June 2024.</p></sec><sec id="Sec2"><title>TMAO metaorganismal pathway</title><p id="Par6">TMAO is a common organic compound found in animals, plants and fungi [<xref ref-type="bibr" rid="CR8">8</xref>]. In humans, most TMAO is produced in the liver through the oxygenation of trimethylamine (TMA) by flavin-containing monooxygenase-3 (FMO3). TMA is a toxic and odorous byproduct of gut bacterial metabolism of choline, L-carnitine, betaine, and phosphatidylcholine, which are abundant in red meat [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Due to this connection, the TMA/TMAO pathway has been postulated as a potential link between red meat consumption and increased cardiovascular risk [<xref ref-type="bibr" rid="CR10">10</xref>]. However, fish and other seafood, which are considered healthy, provide a direct source of TMAO, as marine animals accumulate large amount of this molecule [<xref ref-type="bibr" rid="CR11">11</xref>]. Nonetheless, broad-spectrum antibiotic treatment has been shown to reduce TMAO concentrations in the blood of both humans and laboratory animals, supporting the idea that gut bacteria are the primary source of TMAO in the bloodstream. Plasma levels of TMAO typically range from 3 &#x003bc;mol/L in healthy individuals to 40 &#x003bc;mol/L in those with kidney failure [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Kidneys actively excrete TMAO [<xref ref-type="bibr" rid="CR13">13</xref>], which may explain why kidney function is a major determinant of plasma TMAO concentration [<xref ref-type="bibr" rid="CR14">14</xref>]. Relatively high inter- and intra-individual variations in plasma TMAO level are observed in humans [<xref ref-type="bibr" rid="CR15">15</xref>], which may be attributed not only to kidney function but also to amount of dietary choline, carnitine, TMA, and TMAO, as well as metabolic activity of gut microbiota or FMO3.</p><p id="Par7">Numerous experimental studies have been performed to determine whether TMAO promotes cardiovascular disease. TMAO supplementation or its dietary precursors have been shown to increase atherosclerotic plaque formation in mice [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. However, some studies contradict these findings, with Collins et al. even suggesting a protective effect of TMAO against atherosclerosis [<xref ref-type="bibr" rid="CR18">18</xref>]. TMAO has also been shown to increase heart failure severity in mice, with some research indicating that it may induce cardiac fibrosis and disrupt heart energy metabolism [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Despite this, studies by Querio et al. [<xref ref-type="bibr" rid="CR22">22</xref>] and others [<xref ref-type="bibr" rid="CR23">23</xref>] do not support the damaging effects of TMAO on cardiomyocytes. Therefore, it remains unclear whether elevated TMAO levels in cardiovascular disease reflect its harmful nature or if they are merely a confounder. Alternatively, the increase in TMAO could be part of an adaptive response [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par8">It is important to note that TMAO is an osmolyte&#x02014;a small compound capable of maintaining cell volume and counteracting the protein-destabilizing effects of osmotic and hydrostatic stresses. Deep-sea animals utilize this property of TMAO [<xref ref-type="bibr" rid="CR25">25</xref>], however, human tissues are subjected to high osmotic and hydrostatic pressures as well. For instance, cells in the kidney medulla function in an environment where osmolarity is three to five times higher than that of plasma. To produce concentrated urine, the kidneys accumulate sodium and urea, creating a high osmotic gradient in the medullary region. It has been reported that kidneys also accumulate TMAO, which may act as an osmotic agent and protect kidney cell proteins from disturbances caused by urea [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par9">Osmotic stress also plays a role in pathological conditions such as diabetes, where hyperglycemia can cause significant osmotic changes. In fact, diabetes-associated disturbances in osmoregulation are very likely to contribute to the development of cellular dysfunctions and late diabetic complications [<xref ref-type="bibr" rid="CR28">28</xref>]. Research has demonstrated that diabetes alters the concentration of osmolytes, e.g. decreases taurine and increases sorbitol intracellular accumulation [<xref ref-type="bibr" rid="CR28">28</xref>]. Arguably, changes in TMAO concentration observed in diabetes may also reflect these shifts in osmolyte levels. While it remains to be determined whether this is an adaptive response, TMAO has been shown to act as a chemical chaperone in diabetes, a topic that will be explored in more detail later.</p></sec><sec id="Sec3"><title>Plasma and urine TMAO excretion is increased in diabetes</title><p id="Par10">Although observational studies do not provide direct evidence of causal relationships, identifying biomarkers associated with disease across various patient cohorts is a crucial step in establishing new intervention targets or risk markers. Elevated TMAO levels in diabetes have been reported as early as 1998, when Messana et al. demonstrated higher TMAO concentrations in the urine of diabetic patients, independent of metabolic control, glucosuria, and HbA1c levels [<xref ref-type="bibr" rid="CR29">29</xref>]. Since then, a number of studies have shown the association between plasma TMAO concentration and diabetes in various cohorts, including population-based [<xref ref-type="bibr" rid="CR30">30</xref>] as well as different cardiovascular disease cohorts [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. In 2019, Zhuang et al. conducted a meta-analysis that included 12 studies with a total of 15,314 participants, revealing a dose-dependent association between circulating TMAO levels and diabetes [<xref ref-type="bibr" rid="CR33">33</xref>]. The analysis included patients with stable coronary artery disease [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>], heart failure [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>], patients after acute coronary event [<xref ref-type="bibr" rid="CR38">38</xref>], patients undergoing cardiovascular surgery [<xref ref-type="bibr" rid="CR39">39</xref>] or coronary angiography [<xref ref-type="bibr" rid="CR40">40</xref>], as well as population-based [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR41">41</xref>] and several diabetes case-control studies [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. Among these, only one study reported no difference in TMAO levels between diabetic and non-diabetic patients [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par11">Subsequent studies have largely confirmed the meta-analysis findings, though some inconsistencies persist. Namely, TMAO levels were associated with diabetes in coronary heart disease patients [<xref ref-type="bibr" rid="CR45">45</xref>], in obese population [<xref ref-type="bibr" rid="CR46">46</xref>], in patients at a high risk of cardiovascular events [<xref ref-type="bibr" rid="CR47">47</xref>], two large cohorts of general population [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and smaller case-control study [<xref ref-type="bibr" rid="CR50">50</xref>]. Additionally, TMAO plasma concentrations were found to be higher in patients with type 2 diabetes compared to both healthy controls and patients with acute myocardial infarction [<xref ref-type="bibr" rid="CR51">51</xref>]. In fact, despite the fact that TMAO was initially recognized with respect to atherosclerosis, there are studies showing no significant association between TMAO and atherosclerotic cardiovascular disease, and suggesting it is the presence or absence of diabetes that has a decisive effect on plasma TMAO levels [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. In this regard, Yu et al. directly revealed that a history of diabetes magnified the association between TMAO and coronary heart disease, with high TMAO levels associated with odds ratios of 6.21 and 1.56 in diabetic and non-diabetic subjects, respectively [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par12">However, some studies demonstrated that TMAO precursors like choline [<xref ref-type="bibr" rid="CR54">54</xref>] or TMA [<xref ref-type="bibr" rid="CR55">55</xref>], rather than TMAO itself, are more significantly associated with type 2 diabetes. Huo et al. showed that the TMAO/TMA ratio decreased gradually during the transition from healthy control through T2DM without microalbuminuria to T2DM with microalbuminuria [<xref ref-type="bibr" rid="CR55">55</xref>]. In fact, virtually none of other above-mentioned studies measured the concentration of TMA so it may be speculated that TMA would turn out to be a better marker of diabetes than TMAO. Additionally, TMAO may not be a suitable marker for diabetes in certain populations, as demonstrated in HIV patients [<xref ref-type="bibr" rid="CR56">56</xref>]. Last but not least, the vast majority of studies focus on type 2 diabetes, with much weaker evidence supporting an association between TMAO and other types of diabetes. In fact, to the best of our knowledge, currently there are no studies directly demonstrating TMAO elevation in patients with type 1 diabetes. Although some studies [<xref ref-type="bibr" rid="CR32">32</xref>] included diabetes patients in general, according to definition of diabetes provided by WHO [<xref ref-type="bibr" rid="CR57">57</xref>], it should be noted that type 2 diabetes accounts for more than 90% of all diabetes cases [<xref ref-type="bibr" rid="CR58">58</xref>]. Consequently, the demonstrated associations may not be as significant for type 1 diabetes patients.</p><p id="Par13">Several studies have also examined the correlation between TMAO and gestational diabetes mellitus (GDM). A study by Lin et al. found that TMAO levels in maternal and cord plasma were elevated in women with GDM. Intriguingly, the study suggested a protective role for TMAO in promoting placental and fetal development by inhibiting neutrophil extracellular trap (NET) formation [<xref ref-type="bibr" rid="CR59">59</xref>]. Another study reported an association between TMAO levels in maternal blood, but not in cord plasma, with GDM [<xref ref-type="bibr" rid="CR60">60</xref>]. Conversely, Barzilay et al. observed differences in TMAO concentrations between the GDM and control groups only in cord blood, not in maternal blood [<xref ref-type="bibr" rid="CR61">61</xref>]. On the other hand, two other research groups found no association between TMAO and GDM [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Furthermore, Huo et al. demonstrated that it was TMA that was linearly associated with GDM, whereas TMA precursors and TMAO were inversely associated with GDM. Interestingly, the authors suggested that the association between TMAO and the risk of GDM may be <italic>U</italic>-shaped [<xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par14">Observational studies play a crucial role in identifying associations; however, they are subject to significant limitations. One major limitation is the presence of confounding factors, as variables such as dietary patterns, kidney function, age, and comorbidities can significantly influence TMAO levels. Additionally, the issue of reverse causality must be considered, wherein disease states may influence TMAO production or clearance, rather than TMAO being the causal factor in disease development. Furthermore, substantial heterogeneity across studies complicates the interpretation of results. Variability in study populations, methods used to measure TMAO, and definitions of health outcomes contribute to inconsistencies, making it challenging to draw definitive conclusions from observational research.</p></sec><sec id="Sec4"><title>TMAO and risk of diabetes</title><p id="Par15">With the growing, albeit inconsistent, evidence linking TMAO with diabetes, research is increasingly focused on evaluating TMAO&#x02019;s potential as a risk biomarker for incident diabetes (see Table <xref rid="Tab1" ref-type="table">1</xref>). Prospective cohort studies address many limitations of cross-sectional research and show temporal relationships between baseline TMAO levels and subsequent diabetes development. Regarding type 2 diabetes, two research groups identified a positive association between higher baseline TMAO levels and an increased risk of developing diabetes [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. In the study by Huang et al., both initial TMAO levels and long-term changes in TMAO were associated with incident type 2 diabetes [<xref ref-type="bibr" rid="CR66">66</xref>]. However, three other studies found no such association [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>], although TMAO correlated with markers of insulin sensitivity (HOMA2-IR, fasting insulin). An analysis by Friedrich et al. suggests that sex differences may contribute to these discrepancies. They found that increased TMAO levels were associated with a higher risk of diabetes, but only in women, not in men [<xref ref-type="bibr" rid="CR69">69</xref>]. Complicating matters further, Papandreou et al. reported a negative association, indicating that higher TMAO levels were linked with a lower risk of future diabetes [<xref ref-type="bibr" rid="CR70">70</xref>]. This contradictory finding highlights the complexity of TMAO metabolism and suggests potential protective mechanisms that may operate under certain conditions. Also, high intra- and inter-individual variability of TMAO concentrations in diabetic patients may partially explain these inconsistent observations [<xref ref-type="bibr" rid="CR71">71</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of the prospective studies evaluating the association of baseline TMAO with incident diabetes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Type of diabetes</th><th>Study population</th><th>Mean follow-up duration</th><th>TMAO association with incident diabetes risk</th><th>Comments</th></tr></thead><tbody><tr><td>Svingen et al. [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals with suspected stable angina pectoris</td><td>7.5 years</td><td>No association</td><td>TMAO correlated positively with HOMA2-IR.</td></tr><tr><td>Friedrich et al. [<xref ref-type="bibr" rid="CR69">69</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals</td><td>5 years</td><td>Higher risk in women: ROC<sup>AUC</sup>&#x02009;=&#x02009;0.903; No association in men</td><td>Sex differences</td></tr><tr><td>Papandreou et al. [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals at high risk of cardiovascular disease</td><td>3.8 years</td><td>Lower risk (HR&#x02009;=&#x02009;0.52)</td><td/></tr><tr><td>Li et al. [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals in middle-aged and older adults</td><td>8.9 years</td><td>Higher risk (HR&#x02009;=&#x02009;1.42)</td><td>TMAO was associated with fasting glucose but not with HbA1c, insulin or HOMA-IR.</td></tr><tr><td>Lemaitre et al. [<xref ref-type="bibr" rid="CR68">68</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals at high risk of cardiovascular disease</td><td>12.1 years</td><td>No association</td><td>TMAO was associated with fasting insulin.</td></tr><tr><td>Huang et al. [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals aged above 35 years</td><td>1.85 years</td><td>Higher risk (OR&#x02009;=&#x02009;8.68)</td><td>Both initial serum TMAO levels and long-term serum TMAO changes were associated with incident T2D.</td></tr><tr><td>Sawicki et al. [<xref ref-type="bibr" rid="CR78">78</xref>]</td><td>Type 2 diabetes</td><td>Nondiabetic individuals; two cohorts</td><td>3 years and 6 years for different cohorts</td><td>No association</td><td>TMAO was associated with higher fasting glucose.</td></tr><tr><td>Li et al. [<xref ref-type="bibr" rid="CR72">72</xref>]</td><td>GDM</td><td>Nondiabetic pregnant women, diagnosed with Gestational Diabetes Mellitus (GDM)</td><td>4&#x02013;12 weeks</td><td>Higher risk (OR&#x02009;=&#x02009;1.22)</td><td/></tr></tbody></table></table-wrap></p><p id="Par16">Similarly, studies evaluating the risk of developing GDM in pregnancy reported contradictory results [<xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. Moreover, Liu et al. found that it was actually TMA, rather than TMAO, that was exaggerating the risk of GDM [<xref ref-type="bibr" rid="CR73">73</xref>], once again highlighting this direct TMAO precursor as a potentially more reliable biomarker candidate.</p><p id="Par17">Importantly, the conflicting results surrounding TMAO provide no definitive insight into its causal role in diabetes pathogenesis. To address this, Jia et al. conducted a bidirectional Mendelian randomization analysis to explore the potential causal effect of TMAO on diabetes. Despite the limitations of Mendelian randomization like genetic pleiotropy, it can still offer a more robust estimate of causality than conventional observational studies. Utilizing summary data from genome-wide association studies, they found that genetically predicted higher TMAO levels were not associated with an increased risk of type 2 diabetes or other cardiometabolic diseases. Instead, they observed reverse causality, suggesting that it is diabetes and kidney disease that elevate TMAO levels [<xref ref-type="bibr" rid="CR74">74</xref>]. Miao et al. proposed the mechanism of this reverse causality showing that insulin resistance upregulates the activity of FMO-3 and hence increases TMAO levels. Specifically, they demonstrated that one of insulin&#x02019;s most significant effects on the mouse liver in vivo is to suppress FMO3 and TMAO, a function that is impaired in insulin-resistant states [<xref ref-type="bibr" rid="CR75">75</xref>]. Therefore, TMAO may be an indicator of hepatic insulin resistance, which partially explains the TMAO-associated risk of cardiovascular events and diabetes. Although studies have often adjusted for obesity-related factors, such as body mass index and diabetes, these adjustments likely do not fully encompass the impact of hepatic insulin resistance [<xref ref-type="bibr" rid="CR76">76</xref>]. The identification of TMAO as a potential biomarker of hepatic insulin resistance offers a novel perspective on its clinical utility, suggesting it may provide information about specific metabolic dysfunctions that complement traditional diabetes markers.</p><p id="Par18">Adding to this already complex picture, it has been repeatedly reported that, unlike TMAO and choline [<xref ref-type="bibr" rid="CR77">77</xref>], another TMAO precursor, betaine, is negatively correlated with diabetes risk [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. This raises the interesting possibility that diabetes may alter gut microbiota metabolism of these compounds, potentially inhibiting the two-step oxidation of choline to betaine, consequently enhancing the formation of TMA from choline.</p></sec><sec id="Sec5"><title>TMAO and cardiovascular risk in diabetic patients</title><p id="Par19">Diabetes significantly increases the risk of atherosclerotic cardiovascular disease compared to the general population [<xref ref-type="bibr" rid="CR79">79</xref>]. Given the growing data regarding linkage between TMAO and cardiovascular disease, the role of this metabolite in identifying high-risk individuals within the diabetic population warrants close examination. Substantial evidence point to TMAO as a very promising cardiovascular risk biomarker [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. However, in the context of diabetes, data has yielded rather mixed results, offering no clear consensus on this matter.</p><p id="Par20">Table <xref rid="Tab2" ref-type="table">2</xref> summarizes the available studies exploring the relationship between TMAO and cardiovascular risk in individuals with diabetes. Several retrospective observational studies have demonstrated a correlation between elevated TMAO levels and an increased risk of various adverse cardiovascular outcomes in people with type 2 diabetes [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR83">83</xref>]. These findings have been corroborated by several prospective cohort studies [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. Interestingly, some research suggests that diabetes may amplify the relationship between elevated TMAO levels and increased cardiovascular risk [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Conversely, other studies have reported that this association does not hold true for individuals with a history of diabetes [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. In line with these latter findings, some studies conducted on diabetic cohorts have found no significant association between TMAO levels and cardiovascular risk [<xref ref-type="bibr" rid="CR89">89</xref>&#x02013;<xref ref-type="bibr" rid="CR92">92</xref>]. For instance, Schrauben et al. demonstrated that neither plasma TMAO levels nor the fractional excretion of TMAO were linked to an increased incidence of atherosclerotic cardiovascular disease or heart failure [<xref ref-type="bibr" rid="CR90">90</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of the studies evaluating the association of TMAO with cardiovascular risk in diabetes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Study</th><th>Population</th><th>Outcome</th><th>Associations with TMAO</th><th>Comments</th></tr></thead><tbody><tr><td>Tang et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td>Patients with type 2 diabetes, significant proportion of individuals with CVD</td><td><p>3-year MACE</p><p>5-year mortality</p></td><td><p>HR 3.03</p><p>HR 3.63</p></td><td>There was no strong correlation between TMAO and glycemic control.</td></tr><tr><td>Lever et al. [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td>Patients after acute coronary event with type 2 diabetes</td><td><p>Mortality</p><p>myocardial infarction</p><p>heart failure</p><p>unstable angina</p><p>all CV events</p></td><td><p>HR 2.7</p><p>HR 4.0</p><p>HR 4.6</p><p>HR 9.1</p><p>HR 2.0</p></td><td>In subjects without diabetes TMAO was only significant for death and heart failure.</td></tr><tr><td>Croyal et al. [<xref ref-type="bibr" rid="CR84">84</xref>]</td><td>Patients with type 2 diabetes with no evidence of nondiabetic renal disease</td><td><p>MACE</p><p>Mortality</p></td><td><p>HR 1.32</p><p>HR 1.75</p></td><td>Plasma TMAO concentrations were not associated with insulin resistance.</td></tr><tr><td>Winther et al. [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>Individuals with type 1 diabetes</td><td><p>Mortality</p><p>Coronary events</p><p>CVD events</p><p>End-stage renal disease (ESRD)</p></td><td><p>HR 1.19</p><p>HR 1.21</p><p>HR 1.17</p><p>HR 1.67</p></td><td>TMAO was not independently associated with cardiovascular and renal outcomes after adjusting for baseline eGFR.</td></tr><tr><td>Flores-Guerrero et al. [<xref ref-type="bibr" rid="CR82">82</xref>]</td><td>Patients with type 2 diabetes</td><td>CV mortality</td><td>HR 1.93</td><td/></tr><tr><td>Winther et al. [<xref ref-type="bibr" rid="CR92">92</xref>]</td><td>Individuals with type 2 diabetes and albuminuria</td><td><p>Mortality</p><p>CVD mortality</p><p>Risk of CVD</p></td><td><p>no association</p><p>no association</p><p>no association</p></td><td/></tr><tr><td>Sapa et al. [<xref ref-type="bibr" rid="CR83">83</xref>]</td><td>Population of individuals with type 2 diabetes and chronic kidney disease</td><td><p>CV mortality</p><p>Mortality</p><p>Incident kidney failure with replacement therapy</p></td><td><p>HR 1.38</p><p>HR 1.13</p><p>no association</p></td><td>The lower ratio of urine to plasma TMAO concentration but not baseline plasma TMAO was associated with cardiovascular mortality and all-cause mortality.</td></tr><tr><td>Eyileten et al. [<xref ref-type="bibr" rid="CR86">86</xref>]</td><td>Individuals with acute coronary syndrome who underwent percutaneous coronary intervention, with type 2 diabetes</td><td>CV morality</td><td>HR 11.62</td><td/></tr><tr><td>Bao et al. [<xref ref-type="bibr" rid="CR87">87</xref>]</td><td>Individuals newly diagnosed with coronary heart disease, with 48.1% having diabetes</td><td><p>Severity of CAD (correlation with SYNTAX score)</p><p>Subgroup with diabetes</p></td><td><p>&#x003b2;&#x02009;=&#x02009;0.179</p><p>No association</p></td><td>The correlations between TMAO and SYNTAX score did not hold true for subjects who were with histories of diabetes. No adjustment for GFR.</td></tr><tr><td>Cardona et al. [<xref ref-type="bibr" rid="CR89">89</xref>]</td><td>Population of individuals with type 2 diabetes and high atherosclerotic cardiovascular disease risk</td><td>MACE</td><td>no association</td><td>TMAO was not significantly associated with cardiovascular outcomes like MACE, CV death, or revascularization, TMAO levels were not influenced by renal function (eGFR).</td></tr><tr><td>Schrauben et al. [<xref ref-type="bibr" rid="CR90">90</xref>]</td><td>Individuals with type 2 diabetes and chronic kidney disease</td><td><p>Atherosclerotic CVD events</p><p>Incident heart failure events</p></td><td><p>no association</p><p>no association</p></td><td/></tr><tr><td>Yu et al. [<xref ref-type="bibr" rid="CR91">91</xref>]</td><td>Individuals with type 2 diabetes who underwent coronary angiography</td><td><p>Risk of triple vessel disease</p><p>SYNTAX score &#x0003e;22</p><p>Presence of CAD</p></td><td><p>no association</p><p>no association</p><p>no association</p></td><td>No association in models adjusted for eGFR; significant correlation with increased coronary atherosclerotic burden was only observed in patients with reduced kidney function (eGFR &#x0003c;60&#x02009;mL/min/1.73&#x02009;m&#x000b2;).</td></tr><tr><td>Wargny et al. [<xref ref-type="bibr" rid="CR95">95</xref>]</td><td>Individuals with type 2 diabetes</td><td><p>Heart Failure Requiring Hospitalization (HFrH)</p><p>HFrH and/or CV mortality</p><p>All-cause mortality</p></td><td><p>HR 1.32</p><p>HR 1.31</p><p>HR 1.20</p></td><td>No significant associations in fully adjusted models.</td></tr><tr><td>Winther et al. [<xref ref-type="bibr" rid="CR96">96</xref>]</td><td>Individuals with type 1 diabetes</td><td><p>All-cause mortality</p><p>CV mortality</p><p>Combined CVD</p><p>Coronary events</p><p>End-stage renal disease (ESRD)</p></td><td><p>HR 1.00</p><p>HR 1.00</p><p>HR 1.06</p><p>HR 1.03</p><p>HR 1.41</p></td><td>The associations became insignificant after adjusting for baseline eGFR.</td></tr></tbody></table><table-wrap-foot><p><italic>CAD</italic> coronary artery disease, <italic>CV</italic> cardiovascular, <italic>CVD</italic> cardiovascular disease, <italic>MACE</italic> Major Adverse Cardiovascular Events.</p></table-wrap-foot></table-wrap></p><p id="Par21">A critical factor to consider is the strong association between plasma TMAO levels and kidney function, which has been well-documented in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR94">94</xref>]. This association represents a significant confounding factor in TMAO-based risk assessment, as reduced kidney function is independently associated with both elevated TMAO levels and increased cardiovascular risk. Consequently, it is not surprising that many studies observe an attenuation or even a complete loss of the previously observed associations between TMAO and cardiovascular risk after adjusting for estimated glomerular filtration rate (eGFR). For example, in a large prospective cohort study, Wargny et al. initially found that TMAO was associated with an increased risk of heart failure requiring hospitalization. However, after adjusting for eGFR, the association became insignificant [<xref ref-type="bibr" rid="CR95">95</xref>]. A similar observation was reported by Winther et al. in patients with type 1 diabetes, where the association between TMAO levels and mortality or cardiovascular events was abolished after accounting for baseline eGFR [<xref ref-type="bibr" rid="CR96">96</xref>].</p><p id="Par22">In summary, while elevated TMAO levels are frequently associated with heightened cardiovascular and renal risks in diabetic patients, the strength and independence of these associations vary depending on the study population and the adjustments made for other risk factors. Especially, stratification approaches that incorporate both TMAO levels and eGFR may provide more accurate risk prediction than either parameter alone.</p></sec><sec id="Sec6"><title>TMAO and other diabetic complications</title><p id="Par23">Recent research has also explored the relationship between TMAO and various diabetic complications and comorbidities beyond cardiovascular outcomes. TMAO levels have been found to be significantly higher in patients with diabetic retinopathy compared to those with nondiabetic retinopathy, healthy controls, and those with type 2 diabetes mellitus without retinopathy [<xref ref-type="bibr" rid="CR97">97</xref>]. Additionally, elevated plasma TMAO levels have been associated not only with an increased risk of developing diabetic retinopathy but also with greater severity of the condition in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR98">98</xref>]. Although further research is needed to establish causality, a study by Xue et al. suggests that elevated TMAO in patients with proliferative diabetic retinopathy may exacerbate retinal dysfunction, as demonstrated in vitro using retinal cells [<xref ref-type="bibr" rid="CR99">99</xref>].</p><p id="Par24">Beyond retinopathy, TMAO has also been linked to other diabetic complications. For instance, higher TMAO levels have been associated with increased stroke severity [<xref ref-type="bibr" rid="CR100">100</xref>] and mild cognitive impairment in the diabetic patients [<xref ref-type="bibr" rid="CR101">101</xref>]. TMAO levels have also been correlated with osteoporotic complications, including low bone mineral density, osteoporosis, and osteoporotic fractures in patients with type 2 diabetes [<xref ref-type="bibr" rid="CR102">102</xref>]. However, contrasting findings have been reported, with some studies suggesting that TMAO may protect against bone mineral density reduction during weight loss, independent of dietary interventions and baseline diabetes risk factors [<xref ref-type="bibr" rid="CR103">103</xref>].</p><p id="Par25">Figure <xref rid="Fig1" ref-type="fig">1</xref> summarizes links between elevated TMAO levels and diabetic complications.<fig id="Fig1"><label>Fig. 1</label><caption><title>The flowchart summarizing the link between TMAO levels and diabetic complications.</title><p><italic>TMAO</italic> trimethylamine N-oxide.</p></caption><graphic xlink:href="41387_2025_377_Fig1_HTML" id="d33e1069"/></fig></p></sec><sec id="Sec7"><title>Impact of pharmacological treatments and lifestyle interventions on plasma TMAO Levels</title><p id="Par26">The concentration of TMAO in the body can be influenced by various therapies and lifestyle changes. In the context of diabetes, special consideration should be given to drugs like metformin and SGLT2 inhibitors, which are key therapeutic agents in the treatment of this condition. Studies indicate that while metformin effectively lowers TMAO levels in mice [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>], it may conversely increase these levels in humans [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. In patients with newly diagnosed type 2 diabetes, treatment with DPP-4 inhibitor does not significantly affect gut microbiota composition, whereas metformin promotes bile acid production, which may enhance the microbiota&#x02019;s capacity to produce TMAO precursors [<xref ref-type="bibr" rid="CR106">106</xref>]. On the other hand, CCL4 inhibition leads to changes in gut microbiota and normalizes the lipid profile, ultimately reducing TMAO levels [<xref ref-type="bibr" rid="CR108">108</xref>]. GLP-1 receptor agonists and SGLT2 inhibitors can also lower TMAO levels while simultaneously improving metabolic control [<xref ref-type="bibr" rid="CR109">109</xref>, <xref ref-type="bibr" rid="CR110">110</xref>]. However, inhibiting SGLT2, when used after myocardial infarction, may paradoxically increase TMAO levels [<xref ref-type="bibr" rid="CR111">111</xref>].</p><p id="Par27">Lifestyle interventions, which are a key component of diabetes management, also appear to regulate TMAO levels. High-intensity exercise [<xref ref-type="bibr" rid="CR50">50</xref>], and a vegan diet have been shown to lower TMAO levels, positively impacting cardiovascular health [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR113">113</xref>]. In contrast, a Western diet, rich in fats and meat, tends to increase this metabolite [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR114">114</xref>, <xref ref-type="bibr" rid="CR115">115</xref>], although fish consumption was associated with significantly greater increases in circulating TMAO than consumption of eggs or beef [<xref ref-type="bibr" rid="CR116">116</xref>]. Interestingly, some data suggest that Mediterranean diet, along with interventions aimed at increasing the intake of fish, vegetables, and whole grains, does not significantly affect TMAO levels [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR115">115</xref>, <xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. This suggests that TMAO cannot be regarded as a universal biomarker for cardiometabolic risk independent of dietary factors.</p><p id="Par28">Given the frequent co-occurrence of obesity with type 2 diabetes, the impact of bariatric surgery on TMAO levels also deserves attention. One study indicated that vertical sleeve gastrectomy (VSG) results in reduced TMAO levels [<xref ref-type="bibr" rid="CR119">119</xref>], while other studies have found that both VSG and Roux-en-Y gastric bypass (RYGB) significantly reduce body weight without necessarily lowering TMAO levels [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR117">117</xref>]. In some cases, these surgeries even resulted in increased TMAO levels, particularly in patients with type 2 diabetes following RYGB surgery [<xref ref-type="bibr" rid="CR120">120</xref>]. Other research suggests that TMAO levels may decrease in the long term, depending on the type of surgery and individual patient characteristics [<xref ref-type="bibr" rid="CR112">112</xref>]. Additionally, there are potentially more effective alternatives to invasive treatments, such as phospholipase A2, group 1B (PLA2G1B) enzyme inactivation and the use of its inhibitors, which have been shown to effectively reduce TMAO levels and offer metabolic health benefits [<xref ref-type="bibr" rid="CR119">119</xref>].</p><p id="Par29">In conclusion, the varied effects of therapeutic and dietary interventions on TMAO levels underscore the importance of considering diet, lifestyle, and diabetes treatment context when evaluating TMAO&#x02019;s role as a cardiometabolic risk marker.</p></sec><sec id="Sec8"><title>The role of TMAO in diabetes &#x02013; harmful or protective?</title><p id="Par30">The association between TMAO and diabetes risk raises critical questions about its role in disease etiology. Specifically, it remains unclear whether TMAO actively contributes to the development of diabetes, functions as an adaptive response, or merely reflects underlying pathological processes. This ambiguity has fueled increasing scientific interest in investigating the impact of TMAO on glucose homeostasis.</p><p id="Par31">Several studies suggest that the molecule may play a detrimental role in diabetes. For instance, TMAO treatment has been shown to worsen kidney function, inflammation, and fibrosis in rats with diabetic kidney disease [<xref ref-type="bibr" rid="CR121">121</xref>].</p><p id="Par32">Additionally, TMAO has been shown to exacerbate diabetic retinopathy by enhancing the proliferation, migration, and tube formation of retinal cells. It also disrupts vascular integrity and impairs tight junctions, further contributing to the progression of retinal vascular complications [<xref ref-type="bibr" rid="CR122">122</xref>]. Gao et al. further demonstrated that TMAO impairs glucose tolerance, disrupts hepatic insulin signaling pathways, and induces inflammation in adipose tissue in mice fed a high-fat diet [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Supporting these findings, a recent study by Kong et al. revealed that TMAO directly decreases glucose-stimulated insulin secretion (GSIS) in MIN6 cells and primary islets from both mice and humans. The study further demonstrated that prolonged exposure to a TMAO precursor, choline, induced significant &#x003b2;-cell dysfunction. This included endoplasmic reticulum (ER) stress, dedifferentiation, apoptosis, and the disruption of &#x003b2;-cell transcriptional identity, highlighting its potential role in impairing &#x003b2;-cell function. Interestingly, reducing TMAO levels by knocking down FMO3 improved &#x003b2;-cell GSIS, increased &#x003b2;-cell proportion, and enhanced glucose tolerance in both male db/db mice and mice fed a choline-enriched diet [<xref ref-type="bibr" rid="CR125">125</xref>]. Regarding the potential mechanisms of TMAO&#x02019;s action, it has been suggested that TMAO can directly bind to and activate protein kinase R-like endoplasmic reticulum kinase (PERK), an ER stress kinase, which subsequently induces Forkhead box protein O1 (FoxO1). Inhibition of FMO3, which reduces TMAO levels, has been shown to decrease PERK and FoxO1 activation, ultimately improving glucose tolerance [<xref ref-type="bibr" rid="CR126">126</xref>]. Similarly, other studies have reported that TMAO induces the PERK-EIF2&#x003b1;-ER stress signaling axis in ex vivo slices and db/db mice [<xref ref-type="bibr" rid="CR127">127</xref>] and that administration of a Chinese herb ameliorated diabetic cardiomyopathy in mice by reducing serum TMAO levels and suppressing the TMAO/PERK/FoxO1 signaling pathway [<xref ref-type="bibr" rid="CR128">128</xref>].</p><p id="Par33">Conversely, compelling evidence also suggests a protective role for TMAO in the context of diabetes. Notably, chronic subcutaneous administration of TMAO has been shown to enhance glucose tolerance in mice on a high-fat diet. Additionally, TMAO directly stimulates insulin secretion in isolated pancreatic islets, indicating potential benefits in glucose regulation [<xref ref-type="bibr" rid="CR129">129</xref>]. While these findings appear to contradict previously mentioned studies, they align with earlier research by Bai et al. from 1998, which demonstrated that subcutaneous or intraperitoneal TMAO injections lower blood glucose levels [<xref ref-type="bibr" rid="CR130">130</xref>]. These results also support the growing body of evidence that highlights TMAO&#x02019;s role as a chemical chaperone, capable of reducing endoplasmic reticulum (ER) stress in &#x003b2;-cells. Specifically, TMAO has been found to alleviate ER stress in INS-1 cells [<xref ref-type="bibr" rid="CR131">131</xref>] and to protect &#x003b2;-cells and primary islet function under diabetic glucolipotoxic conditions by restoring insulin production, insulin granule formation, and insulin secretion [<xref ref-type="bibr" rid="CR132">132</xref>]. Moreover, TMAO has shown protective effects in liver cells by reducing ER stress and mitigating lipid-induced disruptions in insulin signaling [<xref ref-type="bibr" rid="CR133">133</xref>]. As a chemical chaperone, TMAO also plays a crucial role in preventing protein misfolding and aggregation, which is particularly relevant in the pathogenesis of diabetes. For instance, TMAO has been demonstrated to counteract the formation of amyloid plaques from human islet amyloid polypeptide (amylin) [<xref ref-type="bibr" rid="CR134">134</xref>, <xref ref-type="bibr" rid="CR135">135</xref>]. Misfolding and aggregation of amylin lead to amyloid fibril formation, causing &#x003b2;-cell dysfunction or death, which contributes to the development of type 2 diabetes [<xref ref-type="bibr" rid="CR134">134</xref>]. TMAO significantly enhances the formation of properly folded and compact structures of amylin, thereby preventing its harmful aggregation [<xref ref-type="bibr" rid="CR135">135</xref>]. Evidence also exists that challenges the notion of TMAO exacerbating diabetic complications. For instance, TMAO treatment has been found to mitigate oxidative-nitrative stress in diabetic peripheral neuropathy, suggesting a potential protective effect against certain diabetes-related complications [<xref ref-type="bibr" rid="CR136">136</xref>] and diabetes-induced impairment in gap junctional communication among astrocytes [<xref ref-type="bibr" rid="CR137">137</xref>]. Additionally, TMAO has been reported to ameliorate body mass loss and reproductive complications associated with diabetes in rats [<xref ref-type="bibr" rid="CR138">138</xref>]. Finally, TMAO has been found to improve diabetic wound healing by inhibiting the formation of neutrophil extracellular traps (NETs) and promoting angiogenesis [<xref ref-type="bibr" rid="CR139">139</xref>], similar to its already mentioned beneficial effects observed in placental and fetal development [<xref ref-type="bibr" rid="CR59">59</xref>].</p><p id="Par34">What might account for the discrepancies observed in research on the role of TMAO? We propose three potential explanations.</p><p id="Par35">Firstly, in accordance with a fundamental principle of toxicology, the toxicity of a substance is determined by its dose. It is plausible that TMAO functions as an adaptive, protective mechanism up to a certain concentration, beyond which its harmful effects become apparent. For instance, in the aforementioned study by Krueger et al., TMAO at a concentration of 40&#x02009;&#x000b5;M demonstrated protective effects on islet function. In contrast, &#x003b2;-cells exposed to higher concentrations of 80 and 160&#x02009;&#x000b5;M exhibited impaired mitochondrial viability and reduced glucose-stimulated insulin secretion (GSIS) [<xref ref-type="bibr" rid="CR132">132</xref>]. Accordingly, many studies showing its negative effect have used rather supraphysiological doses of TMAO [<xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR124">124</xref>]. Conversely, Chen et al. suggest that TMAO reduces endoplasmic reticulum stress only at very high (pharmacological) concentrations, such as 300&#x02009;mM, whereas pathophysiological concentrations (50&#x02009;mM) do not produce the same effect [<xref ref-type="bibr" rid="CR126">126</xref>]. All above suggests that TMAO has concentration-dependent biphasic effects.</p><p id="Par36">Secondly, a recent study by Li et al. suggests that the divergent effects of TMAO may be influenced by the route of administration. Specifically, they demonstrated that oral administration of TMAO, but not intraperitoneal injection, resulted in impaired glucose tolerance, elevated lipid levels, and chronic inflammation in adipose tissue [<xref ref-type="bibr" rid="CR140">140</xref>]. Oral TMAO administration may confound results due to gut microbial conversion to TMA, whereas subcutaneous/intraperitoneal routes isolate TMAO-specific effects. Indeed, virtually all studies showing damaging effect of TMAO have used oral administration of TMAO or its precursors [<xref ref-type="bibr" rid="CR121">121</xref>&#x02013;<xref ref-type="bibr" rid="CR125">125</xref>], while after intraperitoneal or subcutaneous administration only the protective effects were observed [<xref ref-type="bibr" rid="CR129">129</xref>, <xref ref-type="bibr" rid="CR130">130</xref>]. Li et al. propose that after oral gavage, TMAO is converted by gut microbiota into TMA, which is the truly harmful compound. Their findings indicate that TMA, rather than TMAO, may impair glucose tolerance [<xref ref-type="bibr" rid="CR140">140</xref>]. Arguably, it is a decrease in TMA that is responsible for various positive effects of dimethylbutanol (DMB, an inhibitor of choline to TMA conversion in the gut), such as improved glucose tolerance and insulin sensitivity [<xref ref-type="bibr" rid="CR141">141</xref>] and decreased the vulnerability of diabetic rats to atrial fibrillation [<xref ref-type="bibr" rid="CR142">142</xref>], even though many researchers attribute these effects to reduced TMAO levels. Although TMA is increasingly recognized as a damaging agent [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR143">143</xref>&#x02013;<xref ref-type="bibr" rid="CR145">145</xref>], its role in cardiometabolic pathology remains largely unexplored.</p><p id="Par37">Lastly, it has been suggested that FMO3, the enzyme responsible for converting TMA into TMAO, might exert harmful effects independently of TMAO levels [<xref ref-type="bibr" rid="CR76">76</xref>], as it may directly boost hepatic lipogenesis and gluconeogenesis [<xref ref-type="bibr" rid="CR146">146</xref>], and support the expression of FoxO1, a key node responsible for the insulin-resistant state [<xref ref-type="bibr" rid="CR75">75</xref>]. However, other studies indicate the protective effect of FMO3, such as reducing lipid-induced endoplasmic reticulum stress in the liver, independent of insulin signaling pathways [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>].</p><p id="Par38">In summary, while some studies suggest that TMAO exacerbates insulin resistance and accelerates disease progression, others propose that it may have protective effects. This discrepancy leaves a key question unresolved: Is TMAO itself pathogenic, or does it simply serve as a biomarker reflecting underlying metabolic dysfunction? It is plausible that elevated TMAO levels primarily indicate hepatic insulin resistance, with their concentrations largely influenced by renal function and dietary intake, rather than playing a direct causal role in the pathogenesis of diabetes.</p><p id="Par39">The possible mechanisms regarding TMAO role in diabetes are summarized in Fig. <xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><title>The possible effects of TMA/TMAO/FMO3 on diabetes pathophysiology.</title><p>Details in the text. ER stress endoplasmic reticulum stress, FoxO1 Forkhead box protein O1, FMO3 Flavin-containing monooxygenase 3, GDM gestational diabetes mellitus, NET neutrophil extracellular traps, PERK protein kinase R-like endoplasmic reticulum kinase, TMA trimethylamine, TMAO trimethylamine N-oxide.</p></caption><graphic xlink:href="41387_2025_377_Fig2_HTML" id="d33e1327"/></fig></p></sec><sec id="Sec9"><title>Clinical applications</title><p id="Par40">Despite extensive research, the immediate clinical utility of TMAO in diabetes management remains limited due to several factors. The substantial variability in TMAO levels&#x02014;affected by diet, kidney function, and microbial metabolism&#x02014;complicates the establishment of standardized reference ranges. Additionally, the bidirectional relationship between TMAO and metabolic dysfunction suggests that elevated levels may reflect a consequence, rather than a cause, of diabetes, reducing its potential as an intervention target.</p><p id="Par41">However, emerging evidence highlights potential applications in specific clinical contexts. In patients with established diabetes, TMAO may serve as a complementary biomarker for hepatic insulin resistance, offering insights not captured by traditional glycemic measures. Furthermore, its association with diabetic complications suggests it could identify high-risk individuals for intensified monitoring and intervention, such as those with elevated TMAO and impaired kidney function who may be at increased risk for cardiovascular complications.</p><p id="Par42">The impact of therapeutic interventions on TMAO metabolism also warrants attention. Research indicates that common diabetes medications&#x02014;such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors&#x02014;affect TMAO levels differently. Understanding these drug-specific effects may help optimize therapeutic strategies.</p><p id="Par43">Several promising research directions may enhance TMAO&#x02019;s clinical utility. Comprehensive metabolic profiling, simultaneously measuring TMAO, TMA, and related precursors (choline, carnitine, betaine), could improve risk stratification compared to isolated TMAO assessment. The varying associations of these metabolites with diabetes risk suggest that a metabolic signature approach may outperform single biomarker strategies.</p><p id="Par44">Longitudinal studies assessing changes in TMAO levels could clarify whether these fluctuations predict disease progression or therapeutic response, offering more insight than static measurements. Integration with emerging biomarkers of insulin resistance and &#x003b2;-cell function may further refine predictive accuracy.</p><p id="Par45">Finally, the role of TMAO in different diabetes phenotypes warrants further exploration. While most research has focused on type 2 diabetes, data on type 1 and monogenic forms are limited. Understanding whether TMAO associations vary by diabetes subtype could improve risk stratification and uncover distinct pathophysiological mechanisms. Additionally, investigating genetic variants in TMA-TMAO pathway enzymes may identify high-risk subpopulations for targeted intervention.</p><sec id="Sec10"><title>Perspectives</title><p id="Par46">Given that patients with diabetes often have elevated levels of TMAO in their blood, the scientific community has been driven by a &#x0201c;gut feeling,&#x0201d; prompting numerous studies to explore the association between TMAO and diabetes risk, as well as its direct effects on diabetes pathophysiology and complications. However, the results have been somewhat conflicting. It is plausible that TMAO is merely an indicator of hepatic insulin resistance, largely influenced by kidney function and diet. The role of TMAO in diabetes pathology remains controversial. Some studies suggest it worsens insulin tolerance and diabetes complications, while others indicate potential protective effects. At the core of the issue lies a fundamental question: What is the true harmful agent&#x02014;TMAO, its precursor TMA, or the liver enzyme FMO3 itself? This critical question emphasizes the need for further research, particularly regarding the direct effects of TMA on glucose homeostasis.</p><p id="Par47">Currently, there is insufficient evidence to classify TMAO as a direct pathogenic factor in diabetes. However, TMAO shows strong potential as a complementary biomarker for clinical risk stratification, as it may reflect aspects of metabolic dysfunction that are not captured by traditional markers like blood glucose levels.</p><p id="Par48">As research into the role of TMAO in diabetes advances, it underscores the complex relationship between gut microbiota and host metabolism. With improved analytical methods and broader access to metabolic profiling, TMAO and related metabolites could become valuable tools for more personalized approaches to assessing diabetes risk, subtyping, and monitoring treatment responses.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>K.J. designed the study, performed a literature research and drafted the manuscript. M.K. contributed to drafting the manuscript and creating tables. M.U. provided important revisions to the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The work was supported by the National Science Centre, Poland grant no: UMO-2020/37/B/NZ5/00366.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Saeedi</surname><given-names>P</given-names></name><name><surname>Petersohn</surname><given-names>I</given-names></name><name><surname>Salpea</surname><given-names>P</given-names></name><name><surname>Malanda</surname><given-names>B</given-names></name><name><surname>Karuranga</surname><given-names>S</given-names></name><name><surname>Unwin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas</article-title><source>Diabetes Res Clin Pract</source><year>2019</year><volume>157</volume><fpage>107843</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2019.107843</pub-id><pub-id pub-id-type="pmid">31518657</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843.<pub-id pub-id-type="pmid">31518657</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Abdellatif</surname><given-names>AM</given-names></name><name><surname>Sarvetnick</surname><given-names>NE</given-names></name></person-group><article-title>Current understanding of the role of gut dysbiosis in type 1 diabetes</article-title><source>J diabetes</source><year>2019</year><volume>11</volume><fpage>632</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.12915</pub-id><pub-id pub-id-type="pmid">30864231</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Abdellatif AM, Sarvetnick NE. Current understanding of the role of gut dysbiosis in type 1 diabetes. J diabetes. 2019;11:632&#x02013;44.<pub-id pub-id-type="pmid">30864231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><etal/></person-group><article-title>A metagenome-wide association study of gut microbiota in type 2 diabetes</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/nature11450</pub-id><pub-id pub-id-type="pmid">23023125</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55&#x02013;60.<pub-id pub-id-type="pmid">23023125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>HK</given-names></name><name><surname>Gudmundsdottir</surname><given-names>V</given-names></name><name><surname>Nielsen</surname><given-names>HB</given-names></name><name><surname>Hyotylainen</surname><given-names>T</given-names></name><name><surname>Nielsen</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>BA</given-names></name><etal/></person-group><article-title>Human gut microbes impact host serum metabolome and insulin sensitivity</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>376</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/nature18646</pub-id><pub-id pub-id-type="pmid">27409811</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature. 2016;535:376&#x02013;81.<pub-id pub-id-type="pmid">27409811</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>Koeth</surname><given-names>RA</given-names></name><name><surname>Britt</surname><given-names>EB</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>1575</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1109400</pub-id><pub-id pub-id-type="pmid">23614584</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Tang WW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368:1575&#x02013;84.<pub-id pub-id-type="pmid">23614584</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yi</surname><given-names>H</given-names></name><name><surname>Kuang</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name></person-group><article-title>Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus</article-title><source>Biomed Pharmacother</source><year>2022</year><volume>149</volume><fpage>112839</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.112839</pub-id><pub-id pub-id-type="pmid">35325852</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Du L, Li Q, Yi H, Kuang T, Tang Y, Fan G. Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus. Biomed Pharmacother. 2022;149:112839.<pub-id pub-id-type="pmid">35325852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Nowi&#x00144;ski</surname><given-names>A</given-names></name><name><surname>Ufnal</surname><given-names>M</given-names></name></person-group><article-title>Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases?</article-title><source>Nutrition</source><year>2018</year><volume>46</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2017.08.001</pub-id><pub-id pub-id-type="pmid">29290360</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Nowi&#x00144;ski A, Ufnal M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases?. Nutrition. 2018;46:7&#x02013;12.<pub-id pub-id-type="pmid">29290360</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ufnal</surname><given-names>M</given-names></name><name><surname>Zadlo</surname><given-names>A</given-names></name><name><surname>Ostaszewski</surname><given-names>R</given-names></name></person-group><article-title>TMAO: a small molecule of great expectations</article-title><source>Nutrition</source><year>2015</year><volume>31</volume><fpage>1317</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.nut.2015.05.006</pub-id><pub-id pub-id-type="pmid">26283574</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ufnal M, Zadlo A, Ostaszewski R. TMAO: a small molecule of great expectations. Nutrition. 2015;31:1317&#x02013;23.<pub-id pub-id-type="pmid">26283574</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisel</surname><given-names>SH</given-names></name><name><surname>Youssef</surname><given-names>M</given-names></name><name><surname>Hensey</surname><given-names>S</given-names></name></person-group><article-title>Conversion of dietary choline to trimethylamine and dimethylamine in rats: dose-response relationship</article-title><source>J Nutr</source><year>1989</year><volume>119</volume><fpage>800</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/jn/119.5.800</pub-id><pub-id pub-id-type="pmid">2723829</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zeisel SH, Youssef M, Hensey S. Conversion of dietary choline to trimethylamine and dimethylamine in rats: dose-response relationship. J Nutr. 1989;119:800&#x02013;4.<pub-id pub-id-type="pmid">2723829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Koeth</surname><given-names>RA</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>Buffa</surname><given-names>JA</given-names></name><name><surname>Org</surname><given-names>E</given-names></name><name><surname>Sheehy</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>576</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nm.3145</pub-id><pub-id pub-id-type="pmid">23563705</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576&#x02013;85.<pub-id pub-id-type="pmid">23563705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Niizeki N, Tanimoto S. Trimethylamine N-Oxide (TMAO) in Seafoods: Shared Mechanisms Between Fish and Humans for Forming Gut-Microbial TMAO: Overview of Animal TMAO-Yield Potential. Food Rev Int. 2024;40:3471&#x02013;86.</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Bain</surname><given-names>MA</given-names></name><name><surname>Faull</surname><given-names>R</given-names></name><name><surname>Fornasini</surname><given-names>G</given-names></name><name><surname>Milne</surname><given-names>RW</given-names></name><name><surname>Evans</surname><given-names>AM</given-names></name></person-group><article-title>Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis</article-title><source>Nephrol Dial Transplant</source><year>2006</year><volume>21</volume><fpage>1300</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfk056</pub-id><pub-id pub-id-type="pmid">16401621</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant. 2006;21:1300&#x02013;4.<pub-id pub-id-type="pmid">16401621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Teft</surname><given-names>WA</given-names></name><name><surname>Morse</surname><given-names>BL</given-names></name><name><surname>Leake</surname><given-names>BF</given-names></name><name><surname>Wilson</surname><given-names>A</given-names></name><name><surname>Mansell</surname><given-names>SE</given-names></name><name><surname>Hegele</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Identification and characterization of trimethylamine-N-oxide uptake and efflux transporters</article-title><source>Mol Pharmaceutics</source><year>2017</year><volume>14</volume><fpage>310</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00937</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Teft WA, Morse BL, Leake BF, Wilson A, Mansell SE, Hegele RA, et al. Identification and characterization of trimethylamine-N-oxide uptake and efflux transporters. Mol Pharmaceutics. 2017;14:310&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Missailidis</surname><given-names>C</given-names></name><name><surname>H&#x000e4;llqvist</surname><given-names>J</given-names></name><name><surname>Qureshi</surname><given-names>AR</given-names></name><name><surname>Barany</surname><given-names>P</given-names></name><name><surname>Heimb&#x000fc;rger</surname><given-names>O</given-names></name><name><surname>Lindholm</surname><given-names>B</given-names></name><etal/></person-group><article-title>Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease</article-title><source>PloS One</source><year>2016</year><volume>11</volume><fpage>e0141738</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0141738</pub-id><pub-id pub-id-type="pmid">26751065</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Missailidis C, H&#x000e4;llqvist J, Qureshi AR, Barany P, Heimb&#x000fc;rger O, Lindholm B, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PloS One. 2016;11:e0141738.<pub-id pub-id-type="pmid">26751065</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>K&#x000fc;hn</surname><given-names>T</given-names></name><name><surname>Rohrmann</surname><given-names>S</given-names></name><name><surname>Sookthai</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Katzke</surname><given-names>V</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><etal/></person-group><article-title>Intra-individual variation of plasma trimethylamine-N-oxide (TMAO), betaine and choline over 1 year</article-title><source>Clin Chem Lab Med</source><year>2017</year><volume>55</volume><fpage>261</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1515/cclm-2016-0374</pub-id><pub-id pub-id-type="pmid">27447240</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">K&#x000fc;hn T, Rohrmann S, Sookthai D, Johnson T, Katzke V, Kaaks R, et al. Intra-individual variation of plasma trimethylamine-N-oxide (TMAO), betaine and choline over 1 year. Clin Chem Lab Med. 2017;55:261&#x02013;8.<pub-id pub-id-type="pmid">27447240</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway</article-title><source>Biomed Pharmacother</source><year>2018</year><volume>97</volume><fpage>941</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2017.11.016</pub-id><pub-id pub-id-type="pmid">29136772</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Geng J, Yang C, Wang B, Zhang X, Hu T, Gu Y, et al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. Biomed Pharmacother. 2018;97:941&#x02013;7.<pub-id pub-id-type="pmid">29136772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Klipfell</surname><given-names>E</given-names></name><name><surname>Bennett</surname><given-names>BJ</given-names></name><name><surname>Koeth</surname><given-names>R</given-names></name><name><surname>Levison</surname><given-names>BS</given-names></name><name><surname>DuGar</surname><given-names>B</given-names></name><etal/></person-group><article-title>Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease</article-title><source>Nature</source><year>2011</year><volume>472</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature09922</pub-id><pub-id pub-id-type="pmid">21475195</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57&#x02013;63.<pub-id pub-id-type="pmid">21475195</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>HL</given-names></name><name><surname>Drazul-Schrader</surname><given-names>D</given-names></name><name><surname>Sulpizio</surname><given-names>AC</given-names></name><name><surname>Koster</surname><given-names>PD</given-names></name><name><surname>Williamson</surname><given-names>Y</given-names></name><name><surname>Adelman</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE&#x02212;/&#x02212; transgenic mice expressing CETP</article-title><source>Atherosclerosis</source><year>2016</year><volume>244</volume><fpage>29</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.10.108</pub-id><pub-id pub-id-type="pmid">26584136</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Collins HL, Drazul-Schrader D, Sulpizio AC, Koster PD, Williamson Y, Adelman SJ, et al. L-Carnitine intake and high trimethylamine N-oxide plasma levels correlate with low aortic lesions in ApoE&#x02212;/&#x02212; transgenic mice expressing CETP. Atherosclerosis. 2016;244:29&#x02013;37.<pub-id pub-id-type="pmid">26584136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Ou</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis</article-title><source>J Mol Cell Cardiol</source><year>2019</year><volume>134</volume><fpage>119</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2019.07.004</pub-id><pub-id pub-id-type="pmid">31299216</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Yang W, Zhang S, Zhu J, Jiang H, Jia D, Ou T, et al. Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis. J Mol Cell Cardiol. 2019;134:119&#x02013;30.<pub-id pub-id-type="pmid">31299216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis</article-title><source>Laboratory Investig</source><year>2019</year><volume>99</volume><fpage>346</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/s41374-018-0091-y</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Li Z, Wu Z, Yan J, Liu H, Liu Q, Deng Y, et al. Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis. Laboratory Investig. 2019;99:346&#x02013;57.</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Makrecka-Kuka</surname><given-names>M</given-names></name><name><surname>Volska</surname><given-names>K</given-names></name><name><surname>Antone</surname><given-names>U</given-names></name><name><surname>Vilskersts</surname><given-names>R</given-names></name><name><surname>Grinberga</surname><given-names>S</given-names></name><name><surname>Bandere</surname><given-names>D</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria</article-title><source>Toxicol Lett</source><year>2017</year><volume>267</volume><fpage>32</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2016.12.017</pub-id><pub-id pub-id-type="pmid">28049038</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Makrecka-Kuka M, Volska K, Antone U, Vilskersts R, Grinberga S, Bandere D, et al. Trimethylamine N-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria. Toxicol Lett. 2017;267:32&#x02013;8.<pub-id pub-id-type="pmid">28049038</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Querio</surname><given-names>G</given-names></name><name><surname>Antoniotti</surname><given-names>S</given-names></name><name><surname>Levi</surname><given-names>R</given-names></name><name><surname>Gallo</surname><given-names>MP</given-names></name></person-group><article-title>Trimethylamine N-oxide does not impact viability, ROS production, and mitochondrial membrane potential of adult rat cardiomyocytes</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>3045</fpage><pub-id pub-id-type="doi">10.3390/ijms20123045</pub-id><pub-id pub-id-type="pmid">31234461</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Querio G, Antoniotti S, Levi R, Gallo MP. Trimethylamine N-oxide does not impact viability, ROS production, and mitochondrial membrane potential of adult rat cardiomyocytes. Int J Mol Sci. 2019;20:3045.<pub-id pub-id-type="pmid">31234461</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Jaworska</surname><given-names>K</given-names></name><name><surname>Hering</surname><given-names>D</given-names></name><name><surname>Mosieniak</surname><given-names>G</given-names></name><name><surname>Bielak-Zmijewska</surname><given-names>A</given-names></name><name><surname>Pilz</surname><given-names>M</given-names></name><name><surname>Konwerski</surname><given-names>M</given-names></name><etal/></person-group><article-title>TMA, a forgotten uremic toxin, but not TMAO, is involved in cardiovascular pathology</article-title><source>Toxins</source><year>2019</year><volume>11</volume><fpage>490</fpage><pub-id pub-id-type="doi">10.3390/toxins11090490</pub-id><pub-id pub-id-type="pmid">31454905</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Jaworska K, Hering D, Mosieniak G, Bielak-Zmijewska A, Pilz M, Konwerski M, et al. TMA, a forgotten uremic toxin, but not TMAO, is involved in cardiovascular pathology. Toxins. 2019;11:490.<pub-id pub-id-type="pmid">31454905</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Ufnal</surname><given-names>M</given-names></name><name><surname>Nowi&#x00144;ski</surname><given-names>A</given-names></name></person-group><article-title>Is increased plasma TMAO a compensatory response to hydrostatic and osmotic stress in cardiovascular diseases?</article-title><source>Med Hypotheses</source><year>2019</year><volume>130</volume><fpage>109271</fpage><pub-id pub-id-type="doi">10.1016/j.mehy.2019.109271</pub-id><pub-id pub-id-type="pmid">31383335</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Ufnal M, Nowi&#x00144;ski A. Is increased plasma TMAO a compensatory response to hydrostatic and osmotic stress in cardiovascular diseases?. Med Hypotheses. 2019;130:109271.<pub-id pub-id-type="pmid">31383335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Yancey</surname><given-names>PH</given-names></name><name><surname>Blake</surname><given-names>WR</given-names></name><name><surname>Conley</surname><given-names>J</given-names></name></person-group><article-title>Unusual organic osmolytes in deep-sea animals: adaptations to hydrostatic pressure and other perturbants</article-title><source>Comparative Biochem Physiol Part A Mol Integr Physiol</source><year>2002</year><volume>133</volume><fpage>667</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/S1095-6433(02)00182-4</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Yancey PH, Blake WR, Conley J. Unusual organic osmolytes in deep-sea animals: adaptations to hydrostatic pressure and other perturbants. Comparative Biochem Physiol Part A Mol Integr Physiol. 2002;133:667&#x02013;76.</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Bolen</surname><given-names>D</given-names></name></person-group><article-title>A naturally occurring protective system in urea-rich cells: mechanism of osmolyte protection of proteins against urea denaturation</article-title><source>Biochemistry</source><year>1997</year><volume>36</volume><fpage>9101</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1021/bi970247h</pub-id><pub-id pub-id-type="pmid">9230042</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Wang A, Bolen D. A naturally occurring protective system in urea-rich cells: mechanism of osmolyte protection of proteins against urea denaturation. Biochemistry. 1997;36:9101&#x02013;8.<pub-id pub-id-type="pmid">9230042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Yancey</surname><given-names>P</given-names></name><name><surname>Rhea</surname><given-names>M</given-names></name><name><surname>Kemp</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>DM</given-names></name></person-group><article-title>Trimethylamine oxide, betaine and other osmolytes in deep-sea animals: depth trends and effects on enzymes under hydrostatic pressure</article-title><source>Cell Mol Biol</source><year>2004</year><volume>50</volume><fpage>371</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15529747</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Yancey P, Rhea M, Kemp K, Bailey DM. Trimethylamine oxide, betaine and other osmolytes in deep-sea animals: depth trends and effects on enzymes under hydrostatic pressure. Cell Mol Biol. 2004;50:371&#x02013;6.<pub-id pub-id-type="pmid">15529747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>SH</given-names></name></person-group><article-title>The role of taurine in diabetes and the development of diabetic complications</article-title><source>Diabetes Metab Res Rev</source><year>2001</year><volume>17</volume><fpage>330</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/dmrr.229</pub-id><pub-id pub-id-type="pmid">11747139</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Hansen SH. The role of taurine in diabetes and the development of diabetic complications. Diabetes Metab Res Rev. 2001;17:330&#x02013;46.<pub-id pub-id-type="pmid">11747139</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Messana</surname><given-names>I</given-names></name><name><surname>Forni</surname><given-names>F</given-names></name><name><surname>Ferrari</surname><given-names>F</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Giardina</surname><given-names>B</given-names></name><name><surname>Zuppi</surname><given-names>C</given-names></name></person-group><article-title>Proton nuclear magnetic resonance spectral profiles of urine in type II diabetic patients</article-title><source>Clin Chem</source><year>1998</year><volume>44</volume><fpage>1529</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/clinchem/44.7.1529</pub-id><pub-id pub-id-type="pmid">9665433</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Messana I, Forni F, Ferrari F, Rossi C, Giardina B, Zuppi C. Proton nuclear magnetic resonance spectral profiles of urine in type II diabetic patients. Clin Chem. 1998;44:1529&#x02013;34.<pub-id pub-id-type="pmid">9665433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Gruppen</surname><given-names>EG</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Connelly</surname><given-names>MA</given-names></name><name><surname>Jeyarajah</surname><given-names>EJ</given-names></name><name><surname>Otvos</surname><given-names>JD</given-names></name><name><surname>Bakker</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>TMAO is associated with mortality: impact of modestly impaired renal function</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>13781</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-13739-9</pub-id><pub-id pub-id-type="pmid">29061990</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Gruppen EG, Garcia E, Connelly MA, Jeyarajah EJ, Otvos JD, Bakker SJ, et al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci Rep. 2017;7:13781.<pub-id pub-id-type="pmid">29061990</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Alcoholado</surname><given-names>L</given-names></name><name><surname>Castellano-Castillo</surname><given-names>D</given-names></name><name><surname>Jord&#x000e1;n-Mart&#x000ed;nez</surname><given-names>L</given-names></name><name><surname>Moreno-Indias</surname><given-names>I</given-names></name><name><surname>Cardila-Cruz</surname><given-names>P</given-names></name><name><surname>Elena</surname><given-names>D</given-names></name><etal/></person-group><article-title>Role of gut microbiota on cardio-metabolic parameters and immunity in coronary artery disease patients with and without type-2 diabetes mellitus</article-title><source>Front Microbiol</source><year>2017</year><volume>8</volume><fpage>1936</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01936</pub-id><pub-id pub-id-type="pmid">29051757</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sanchez-Alcoholado L, Castellano-Castillo D, Jord&#x000e1;n-Mart&#x000ed;nez L, Moreno-Indias I, Cardila-Cruz P, Elena D, et al. Role of gut microbiota on cardio-metabolic parameters and immunity in coronary artery disease patients with and without type-2 diabetes mellitus. Front Microbiol. 2017;8:1936.<pub-id pub-id-type="pmid">29051757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Dambrova</surname><given-names>M</given-names></name><name><surname>Latkovskis</surname><given-names>G</given-names></name><name><surname>Kuka</surname><given-names>J</given-names></name><name><surname>Strele</surname><given-names>I</given-names></name><name><surname>Konrade</surname><given-names>I</given-names></name><name><surname>Grinberga</surname><given-names>S</given-names></name><etal/></person-group><article-title>Diabetes is associated with higher trimethylamine N-oxide plasma levels</article-title><source>Exper Clin Endocrinol diabetes</source><year>2016</year><volume>124</volume><fpage>251</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1569330</pub-id><pub-id pub-id-type="pmid">27123785</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberga S, et al. Diabetes is associated with higher trimethylamine N-oxide plasma levels. Exper Clin Endocrinol diabetes. 2016;124:251&#x02013;6.<pub-id pub-id-type="pmid">27123785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>R</given-names></name><name><surname>Ge</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>P</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Gut microbe&#x02013;generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis</article-title><source>Obesity Rev</source><year>2019</year><volume>20</volume><fpage>883</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1111/obr.12843</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Zhuang R, Ge X, Han L, Yu P, Gong X, Meng Q, et al. Gut microbe&#x02013;generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis. Obesity Rev. 2019;20:883&#x02013;94.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Senthong</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>XS</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Wilson Tang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort</article-title><source>J Am Heart Assoc</source><year>2016</year><volume>5</volume><fpage>e002816</fpage><pub-id pub-id-type="doi">10.1161/JAHA.115.002816</pub-id><pub-id pub-id-type="pmid">27287696</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Wilson Tang W, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc. 2016;5:e002816.<pub-id pub-id-type="pmid">27287696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><etal/></person-group><article-title>Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography</article-title><source>Int J Cardiol</source><year>2018</year><volume>265</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2018.04.126</pub-id><pub-id pub-id-type="pmid">29729869</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Liu X, Xie Z, Sun M, Wang X, Li J, Cui J, et al. Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography. Int J Cardiol. 2018;265:18&#x02013;23.<pub-id pub-id-type="pmid">29729869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Heaney</surname><given-names>LM</given-names></name><name><surname>Bhandari</surname><given-names>SS</given-names></name><name><surname>Jones</surname><given-names>DJ</given-names></name><name><surname>Ng</surname><given-names>LL</given-names></name></person-group><article-title>Trimethylamine N-oxide and prognosis in acute heart failure</article-title><source>Heart</source><year>2016</year><volume>102</volume><fpage>841</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2015-308826</pub-id><pub-id pub-id-type="pmid">26869641</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Suzuki T, Heaney LM, Bhandari SS, Jones DJ, Ng LL. Trimethylamine N-oxide and prognosis in acute heart failure. Heart. 2016;102:841&#x02013;8.<pub-id pub-id-type="pmid">26869641</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Levison</surname><given-names>B</given-names></name><name><surname>Hazen</surname><given-names>JE</given-names></name><name><surname>Donahue</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>64</volume><fpage>1908</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.02.617</pub-id><pub-id pub-id-type="pmid">25444145</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Tang WW, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908&#x02013;14.<pub-id pub-id-type="pmid">25444145</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Lever</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>PM</given-names></name><name><surname>Slow</surname><given-names>S</given-names></name><name><surname>Bellamy</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>JM</given-names></name><name><surname>Ho</surname><given-names>M</given-names></name><etal/></person-group><article-title>Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study</article-title><source>PloS One</source><year>2014</year><volume>9</volume><fpage>e114969</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0114969</pub-id><pub-id pub-id-type="pmid">25493436</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Lever M, George PM, Slow S, Bellamy D, Young JM, Ho M, et al. Betaine and trimethylamine-N-oxide as predictors of cardiovascular outcomes show different patterns in diabetes mellitus: an observational study. PloS One. 2014;9:e114969.<pub-id pub-id-type="pmid">25493436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Mafune</surname><given-names>A</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><name><surname>Tsutsumi</surname><given-names>Y</given-names></name><name><surname>Nakashima</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>I</given-names></name><name><surname>Yokoyama</surname><given-names>K</given-names></name><etal/></person-group><article-title>Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study</article-title><source>Clin Exp Nephrol</source><year>2016</year><volume>20</volume><fpage>731</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s10157-015-1207-y</pub-id><pub-id pub-id-type="pmid">26676906</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Mafune A, Iwamoto T, Tsutsumi Y, Nakashima A, Yamamoto I, Yokoyama K, et al. Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin Exp Nephrol. 2016;20:731&#x02013;9.<pub-id pub-id-type="pmid">26676906</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>DM</given-names></name><name><surname>Allenspach</surname><given-names>M</given-names></name><name><surname>Othman</surname><given-names>A</given-names></name><name><surname>Saely</surname><given-names>CH</given-names></name><name><surname>Muendlein</surname><given-names>A</given-names></name><name><surname>Vonbank</surname><given-names>A</given-names></name><etal/></person-group><article-title>Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control</article-title><source>Atherosclerosis</source><year>2015</year><volume>243</volume><fpage>638</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.10.091</pub-id><pub-id pub-id-type="pmid">26554714</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Mueller DM, Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis. 2015;243:638&#x02013;44.<pub-id pub-id-type="pmid">26554714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Afzaal</surname><given-names>M</given-names></name><name><surname>Saeed</surname><given-names>F</given-names></name><name><surname>Shah</surname><given-names>YA</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Rabail</surname><given-names>R</given-names></name><name><surname>Socol</surname><given-names>CT</given-names></name><etal/></person-group><article-title>Human gut microbiota in health and disease: Unveiling the relationship</article-title><source>Front Microbiol</source><year>2022</year><volume>13</volume><fpage>999001</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2022.999001</pub-id><pub-id pub-id-type="pmid">36225386</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, et al. Human gut microbiota in health and disease: Unveiling the relationship. Front Microbiol. 2022;13:999001.<pub-id pub-id-type="pmid">36225386</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Obeid</surname><given-names>R</given-names></name><name><surname>Awwad</surname><given-names>HM</given-names></name><name><surname>Rabagny</surname><given-names>Y</given-names></name><name><surname>Graeber</surname><given-names>S</given-names></name><name><surname>Herrmann</surname><given-names>W</given-names></name><name><surname>Geisel</surname><given-names>J</given-names></name></person-group><article-title>Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism</article-title><source>Am J Clin Nutr</source><year>2016</year><volume>103</volume><fpage>703</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3945/ajcn.115.121269</pub-id><pub-id pub-id-type="pmid">26864355</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Obeid R, Awwad HM, Rabagny Y, Graeber S, Herrmann W, Geisel J. Plasma trimethylamine N-oxide concentration is associated with choline, phospholipids, and methyl metabolism. Am J Clin Nutr. 2016;103:703&#x02013;11.<pub-id pub-id-type="pmid">26864355</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes</article-title><source>Am J Clin Nutr</source><year>2017</year><volume>106</volume><fpage>888</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.3945/ajcn.117.157107</pub-id><pub-id pub-id-type="pmid">28724646</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Shan Z, Sun T, Huang H, Chen S, Chen L, Luo C, et al. Association between microbiota-dependent metabolite trimethylamine-N-oxide and type 2 diabetes. Am J Clin Nutr. 2017;106:888&#x02013;94.<pub-id pub-id-type="pmid">28724646</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WW</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>XS</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>DS</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus</article-title><source>Clin Chem</source><year>2017</year><volume>63</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2016.263640</pub-id><pub-id pub-id-type="pmid">27864387</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Tang WW, Wang Z, Li XS, Fan Y, Li DS, Wu Y, et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin Chem. 2017;63:297&#x02013;306.<pub-id pub-id-type="pmid">27864387</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Hai</surname><given-names>X</given-names></name></person-group><article-title>The association between plasma levels of trimethylamine N-oxide and the risk of coronary heart disease in Chinese patients with or without type 2 diabetes mellitus</article-title><source>Dis Markers</source><year>2018</year><volume>2018</volume><fpage>1578320</fpage><pub-id pub-id-type="doi">10.1155/2018/1578320</pub-id><pub-id pub-id-type="pmid">30159101</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Dong Z, Liang Z, Guo M, Hu S, Shen Z, Hai X. The association between plasma levels of trimethylamine N-oxide and the risk of coronary heart disease in Chinese patients with or without type 2 diabetes mellitus. Dis Markers. 2018;2018:1578320.<pub-id pub-id-type="pmid">30159101</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Fikri</surname><given-names>AM</given-names></name><name><surname>Smyth</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Al-Abadla</surname><given-names>Z</given-names></name><name><surname>Abusnana</surname><given-names>S</given-names></name><name><surname>Munday</surname><given-names>MR</given-names></name></person-group><article-title>Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE&#x02019;s obese national population using targeted metabolomics</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>17616</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-73384-7</pub-id><pub-id pub-id-type="pmid">33077739</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Fikri AM, Smyth R, Kumar V, Al-Abadla Z, Abusnana S, Munday MR. Pre-diagnostic biomarkers of type 2 diabetes identified in the UAE&#x02019;s obese national population using targeted metabolomics. Sci Rep. 2020;10:17616.<pub-id pub-id-type="pmid">33077739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Senthong</surname><given-names>V</given-names></name><name><surname>Kiatchoosakun</surname><given-names>S</given-names></name><name><surname>Wongvipaporn</surname><given-names>C</given-names></name><name><surname>Phetcharaburanin</surname><given-names>J</given-names></name><name><surname>Tatsanavivat</surname><given-names>P</given-names></name><name><surname>Sritara</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><fpage>14963</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-93803-7</pub-id><pub-id pub-id-type="pmid">34294762</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Senthong V, Kiatchoosakun S, Wongvipaporn C, Phetcharaburanin J, Tatsanavivat P, Sritara P, et al. Gut microbiota-generated metabolite, trimethylamine-N-oxide, and subclinical myocardial damage: a multicenter study from Thailand. Sci Rep. 2021;11:14963.<pub-id pub-id-type="pmid">34294762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Ringel</surname><given-names>C</given-names></name><name><surname>Dittrich</surname><given-names>J</given-names></name><name><surname>Gaudl</surname><given-names>A</given-names></name><name><surname>Schellong</surname><given-names>P</given-names></name><name><surname>Beuchel</surname><given-names>CF</given-names></name><name><surname>Baber</surname><given-names>R</given-names></name><etal/></person-group><article-title>Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome</article-title><source>Atherosclerosis</source><year>2021</year><volume>335</volume><fpage>62</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2021.09.026</pub-id><pub-id pub-id-type="pmid">34583200</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Ringel C, Dittrich J, Gaudl A, Schellong P, Beuchel CF, Baber R, et al. Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome. Atherosclerosis. 2021;335:62&#x02013;7.<pub-id pub-id-type="pmid">34583200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Integrating choline and specific intestinal microbiota to classify type 2 diabetes in adults: a machine learning based metagenomics study</article-title><source>Front Endocrinol</source><year>2022</year><volume>13</volume><fpage>906310</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.906310</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Zeng Q, Zhao M, Wang F, Li Y, Li H, Zheng J, et al. Integrating choline and specific intestinal microbiota to classify type 2 diabetes in adults: a machine learning based metagenomics study. Front Endocrinol. 2022;13:906310.</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalagi</surname><given-names>NA</given-names></name><name><surname>Thota</surname><given-names>RN</given-names></name><name><surname>Stojanovski</surname><given-names>E</given-names></name><name><surname>Alburikan</surname><given-names>KA</given-names></name><name><surname>Garg</surname><given-names>ML</given-names></name></person-group><article-title>Association between plasma trimethylamine N-oxide levels and type 2 diabetes: a case control study</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><fpage>2093</fpage><pub-id pub-id-type="doi">10.3390/nu14102093</pub-id><pub-id pub-id-type="pmid">35631234</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Kalagi NA, Thota RN, Stojanovski E, Alburikan KA, Garg ML. Association between plasma trimethylamine N-oxide levels and type 2 diabetes: a case control study. Nutrients. 2022;14:2093.<pub-id pub-id-type="pmid">35631234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Analysis of two intestinal bacterial metabolites (trimethylamine N-oxide and phenylacetylglutamine) in human serum samples of patients with T2DM and AMI using a liquid chromatography tandem mass spectrometry method</article-title><source>Clinica Chim Acta</source><year>2022</year><volume>536</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2022.09.018</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Tang Y, Zou Y, Cui J, Ma X, Zhang L, Yu S, et al. Analysis of two intestinal bacterial metabolites (trimethylamine N-oxide and phenylacetylglutamine) in human serum samples of patients with T2DM and AMI using a liquid chromatography tandem mass spectrometry method. Clinica Chim Acta. 2022;536:162&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Liang H, Yu A, Wang Z, Zhang N, Wang Q, Gao H, et al. Atherosclerotic patients with diabetes mellitus may break through the threshold of healthy TMAO levels formed by long-term statins therapy. Heliyon. 2023;9:e13657.</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Rivera</surname><given-names>ES</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Q</given-names></name><name><surname>Calcutt</surname><given-names>MW</given-names></name><etal/></person-group><article-title>Urinary levels of trimethylamine-N-oxide and incident coronary heart disease: a prospective investigation among urban Chinese adults</article-title><source>J Am Heart Assoc</source><year>2019</year><volume>8</volume><fpage>e010606</fpage><pub-id pub-id-type="doi">10.1161/JAHA.118.010606</pub-id><pub-id pub-id-type="pmid">30606084</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Yu D, Shu XO, Rivera ES, Zhang X, Cai Q, Calcutt MW, et al. Urinary levels of trimethylamine-N-oxide and incident coronary heart disease: a prospective investigation among urban Chinese adults. J Am Heart Assoc. 2019;8:e010606.<pub-id pub-id-type="pmid">30606084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Qi S, Liu L, He S, Wang L, Li J, Sun X. Trimethylamine N-Oxide and related metabolites in the serum and risk of type 2 diabetes in the Chinese population: a case-control study. Diabetes Metab Syndr Obes. 2023;16:547&#x02013;55.</mixed-citation></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Enhanced trimethylamine metabolism and gut dysbiosis in type 2 diabetes mellitus with microalbumin</article-title><source>Front Endocrinol</source><year>2023</year><volume>14</volume><fpage>1257457</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1257457</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Huo L, Li H, Zhu M, Liu Y, Ren L, Hu J, et al. Enhanced trimethylamine metabolism and gut dysbiosis in type 2 diabetes mellitus with microalbumin. Front Endocrinol. 2023;14:1257457.</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Hove-Skovsgaard</surname><given-names>M</given-names></name><name><surname>Gaardbo</surname><given-names>JC</given-names></name><name><surname>Kolte</surname><given-names>L</given-names></name><name><surname>Winding</surname><given-names>K</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><name><surname>Svardal</surname><given-names>A</given-names></name><etal/></person-group><article-title>HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s12879-017-2334-8</pub-id><pub-id pub-id-type="pmid">28049444</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Hove-Skovsgaard M, Gaardbo JC, Kolte L, Winding K, Seljeflot I, Svardal A, et al. HIV-infected persons with type 2 diabetes show evidence of endothelial dysfunction and increased inflammation. BMC Infect Dis. 2017;17:1&#x02013;8.<pub-id pub-id-type="pmid">28049444</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KGMM</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation</article-title><source>Diabetic Med</source><year>1998</year><volume>15</volume><fpage>539</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9136(199807)15:7&#x0003c;539::AID-DIA668&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9686693</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med. 1998;15:539&#x02013;53.<pub-id pub-id-type="pmid">9686693</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>Z-H</given-names></name><name><surname>Qiang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention</article-title><source>BMC Public Health</source><year>2020</year><volume>20</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12889-020-09502-x</pub-id><pub-id pub-id-type="pmid">31898494</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Liu J, Ren Z-H, Qiang H, Wu J, Shen M, Zhang L, et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20:1&#x02013;12.<pub-id pub-id-type="pmid">31898494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>The choline metabolite TMAO inhibits NETosis and promotes placental development in GDM of humans and mice</article-title><source>Diabetes</source><year>2021</year><volume>70</volume><fpage>2250</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2337/db21-0188</pub-id><pub-id pub-id-type="pmid">34315726</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Lin X, Zhang Y, He X, Chen Y, Chen N, Liu J, et al. The choline metabolite TMAO inhibits NETosis and promotes placental development in GDM of humans and mice. Diabetes. 2021;70:2250&#x02013;63.<pub-id pub-id-type="pmid">34315726</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>McArthur</surname><given-names>KL</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Buckley</surname><given-names>JP</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide and its precursors are associated with gestational diabetes mellitus and pre-eclampsia in the boston birth cohort</article-title><source>Current Dev Nutr</source><year>2022</year><volume>6</volume><fpage>nzac108</fpage><pub-id pub-id-type="doi">10.1093/cdn/nzac108</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">McArthur KL, Zhang M, Hong X, Wang G, Buckley JP, Wang X, et al. Trimethylamine N-oxide and its precursors are associated with gestational diabetes mellitus and pre-eclampsia in the boston birth cohort. Current Dev Nutr. 2022;6:nzac108.</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Barzilay</surname><given-names>E</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Plumptre</surname><given-names>L</given-names></name><name><surname>Masih</surname><given-names>SP</given-names></name><name><surname>Sohn</surname><given-names>K-J</given-names></name><name><surname>Visentin</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Fetal one-carbon nutrient concentrations may be affected by gestational diabetes</article-title><source>Nutr Res</source><year>2018</year><volume>55</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2018.04.010</pub-id><pub-id pub-id-type="pmid">29914628</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Barzilay E, Moon A, Plumptre L, Masih SP, Sohn K-J, Visentin CE, et al. Fetal one-carbon nutrient concentrations may be affected by gestational diabetes. Nutr Res. 2018;55:57&#x02013;64.<pub-id pub-id-type="pmid">29914628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Alterations of gut microbiota-derived metabolites in gestational diabetes mellitus and clinical significance</article-title><source>J Clin Lab Anal</source><year>2022</year><volume>36</volume><fpage>e24333</fpage><pub-id pub-id-type="doi">10.1002/jcla.24333</pub-id><pub-id pub-id-type="pmid">35285096</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Gao Y, Chen H, Li J, Ren S, Yang Z, Zhou Y, et al. Alterations of gut microbiota-derived metabolites in gestational diabetes mellitus and clinical significance. J Clin Lab Anal. 2022;36:e24333.<pub-id pub-id-type="pmid">35285096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">Zhou Z, Yao Y, Sun Y, Wang X, Huang S, Hou J, et al. Serum betaine and dimethylglycine in mid-pregnancy and the risk of gestational diabetes mellitus: a case-control study. Endocrine. 2024;85:1&#x02013;11.</mixed-citation></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y-F</given-names></name><name><surname>Li</surname><given-names>S-N</given-names></name><name><surname>Shao</surname><given-names>P</given-names></name><name><surname>Leng</surname><given-names>J</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide metabolites in early pregnancy and risk of gestational diabetes: a nested case-control study</article-title><source>J Clin Endocrinol Metab</source><year>2019</year><volume>104</volume><fpage>5529</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1210/jc.2019-00710</pub-id><pub-id pub-id-type="pmid">31373635</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Huo X, Li J, Cao Y-F, Li S-N, Shao P, Leng J, et al. Trimethylamine N-oxide metabolites in early pregnancy and risk of gestational diabetes: a nested case-control study. J Clin Endocrinol Metab. 2019;104:5529&#x02013;39.<pub-id pub-id-type="pmid">31373635</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S-y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X-t</given-names></name><name><surname>Fang</surname><given-names>A-p</given-names></name><name><surname>Chen</surname><given-names>Y-m</given-names></name><name><surname>Huang</surname><given-names>R-z</given-names></name><etal/></person-group><article-title>Serum trimethylamine-N-oxide is associated with incident type 2 diabetes in middle-aged and older adults: a prospective cohort study</article-title><source>J Transl Med</source><year>2022</year><volume>20</volume><fpage>374</fpage><pub-id pub-id-type="doi">10.1186/s12967-022-03581-7</pub-id><pub-id pub-id-type="pmid">35982495</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Li S-y, Chen S, Lu X-t, Fang A-p, Chen Y-m, Huang R-z, et al. Serum trimethylamine-N-oxide is associated with incident type 2 diabetes in middle-aged and older adults: a prospective cohort study. J Transl Med. 2022;20:374.<pub-id pub-id-type="pmid">35982495</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Ruan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Dynamic changes in gut microbiota-derived metabolite trimethylamine-N-oxide and risk of type 2 diabetes mellitus: potential for dietary changes in diabetes prevention</article-title><source>Nutrients</source><year>2024</year><volume>16</volume><fpage>1711</fpage><pub-id pub-id-type="doi">10.3390/nu16111711</pub-id><pub-id pub-id-type="pmid">38892643</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Huang Y, Wu Y, Zhang Y, Bai H, Peng R, Ruan W, et al. Dynamic changes in gut microbiota-derived metabolite trimethylamine-N-oxide and risk of type 2 diabetes mellitus: potential for dietary changes in diabetes prevention. Nutrients. 2024;16:1711.<pub-id pub-id-type="pmid">38892643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Svingen</surname><given-names>GF</given-names></name><name><surname>Schartum-Hansen</surname><given-names>H</given-names></name><name><surname>Pedersen</surname><given-names>ER</given-names></name><name><surname>Ueland</surname><given-names>PM</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Mellgren</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prospective associations of systemic and urinary choline metabolites with incident type 2 diabetes</article-title><source>Clinical Chem</source><year>2016</year><volume>62</volume><fpage>755</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2015.250761</pub-id><pub-id pub-id-type="pmid">26980210</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Svingen GF, Schartum-Hansen H, Pedersen ER, Ueland PM, Tell GS, Mellgren G, et al. Prospective associations of systemic and urinary choline metabolites with incident type 2 diabetes. Clinical Chem. 2016;62:755&#x02013;65.<pub-id pub-id-type="pmid">26980210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Lemaitre</surname><given-names>RN</given-names></name><name><surname>Jensen</surname><given-names>PN</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fretts</surname><given-names>AM</given-names></name><name><surname>McKnight</surname><given-names>B</given-names></name><name><surname>Nemet</surname><given-names>I</given-names></name><etal/></person-group><article-title>Association of trimethylamine N-oxide and related metabolites in plasma and incident type 2 diabetes: the cardiovascular health study</article-title><source>JAMA Netw open</source><year>2021</year><volume>4</volume><fpage>e2122844-e</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.22844</pub-id><pub-id pub-id-type="pmid">34448864</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Lemaitre RN, Jensen PN, Wang Z, Fretts AM, McKnight B, Nemet I, et al. Association of trimethylamine N-oxide and related metabolites in plasma and incident type 2 diabetes: the cardiovascular health study. JAMA Netw open. 2021;4:e2122844-e.<pub-id pub-id-type="pmid">34448864</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>N</given-names></name><name><surname>Budde</surname><given-names>K</given-names></name><name><surname>Suhre</surname><given-names>K</given-names></name><name><surname>V&#x000f6;lker</surname><given-names>U</given-names></name><name><surname>John</surname><given-names>U</given-names></name><name><surname>Felix</surname><given-names>SB</given-names></name><etal/></person-group><article-title>Sex differences in urine metabolites related with risk of diabetes using NMR spectroscopy: results of the study of health in pomerania</article-title><source>Metabolomics</source><year>2015</year><volume>11</volume><fpage>1405</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s11306-015-0795-6</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Friedrich N, Budde K, Suhre K, V&#x000f6;lker U, John U, Felix SB, et al. Sex differences in urine metabolites related with risk of diabetes using NMR spectroscopy: results of the study of health in pomerania. Metabolomics. 2015;11:1405&#x02013;15.</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Papandreou</surname><given-names>C</given-names></name><name><surname>Bull&#x000f3;</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Ruiz-Canela</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Guasch-Ferr&#x000e9;</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevenci&#x000f3;n con Dieta Mediterr&#x000e1;nea (PREDIMED) trial</article-title><source>Am J Clin Nutr</source><year>2018</year><volume>108</volume><fpage>163</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqy058</pub-id><pub-id pub-id-type="pmid">29982310</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Papandreou C, Bull&#x000f3; M, Zheng Y, Ruiz-Canela M, Yu E, Guasch-Ferr&#x000e9; M, et al. Plasma trimethylamine-N-oxide and related metabolites are associated with type 2 diabetes risk in the Prevenci&#x000f3;n con Dieta Mediterr&#x000e1;nea (PREDIMED) trial. Am J Clin Nutr. 2018;108:163&#x02013;73.<pub-id pub-id-type="pmid">29982310</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>McEntyre</surname><given-names>CJ</given-names></name><name><surname>Lever</surname><given-names>M</given-names></name><name><surname>Chambers</surname><given-names>ST</given-names></name><name><surname>George</surname><given-names>PM</given-names></name><name><surname>Slow</surname><given-names>S</given-names></name><name><surname>Elmslie</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Variation of betaine, N, N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period</article-title><source>Ann Clin Biochem</source><year>2015</year><volume>52</volume><fpage>352</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1177/0004563214545346</pub-id><pub-id pub-id-type="pmid">25013088</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">McEntyre CJ, Lever M, Chambers ST, George PM, Slow S, Elmslie JL, et al. Variation of betaine, N, N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period. Ann Clin Biochem. 2015;52:352&#x02013;60.<pub-id pub-id-type="pmid">25013088</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus</article-title><source>Am J Clin Nutr</source><year>2018</year><volume>108</volume><fpage>603</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqy116</pub-id><pub-id pub-id-type="pmid">30535087</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Li P, Zhong C, Li S, Sun T, Huang H, Chen X, et al. Plasma concentration of trimethylamine-N-oxide and risk of gestational diabetes mellitus. Am J Clin Nutr. 2018;108:603&#x02013;10.<pub-id pub-id-type="pmid">30535087</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Leng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Ceramides and their interactive effects with trimethylamine-N-oxide metabolites on risk of gestational diabetes: a nested case-control study</article-title><source>Diabetes Res Clin Pract</source><year>2021</year><volume>171</volume><fpage>108606</fpage><pub-id pub-id-type="doi">10.1016/j.diabres.2020.108606</pub-id><pub-id pub-id-type="pmid">33310119</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Liu J, Li J, Yang K, Leng J, Li W, Yang W, et al. Ceramides and their interactive effects with trimethylamine-N-oxide metabolites on risk of gestational diabetes: a nested case-control study. Diabetes Res Clin Pract. 2021;171:108606.<pub-id pub-id-type="pmid">33310119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Dou</surname><given-names>P</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Assessment of causal direction between gut microbiota&#x02013;dependent metabolites and cardiometabolic health: a bidirectional Mendelian randomization analysis</article-title><source>Diabetes</source><year>2019</year><volume>68</volume><fpage>1747</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.2337/db19-0153</pub-id><pub-id pub-id-type="pmid">31167879</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of causal direction between gut microbiota&#x02013;dependent metabolites and cardiometabolic health: a bidirectional Mendelian randomization analysis. Diabetes. 2019;68:1747&#x02013;55.<pub-id pub-id-type="pmid">31167879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>J</given-names></name><name><surname>Ling</surname><given-names>AV</given-names></name><name><surname>Manthena</surname><given-names>PV</given-names></name><name><surname>Gearing</surname><given-names>ME</given-names></name><name><surname>Graham</surname><given-names>MJ</given-names></name><name><surname>Crooke</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis</article-title><source>Nat Commun</source><year>2015</year><volume>6</volume><fpage>6498</fpage><pub-id pub-id-type="doi">10.1038/ncomms7498</pub-id><pub-id pub-id-type="pmid">25849138</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Miao J, Ling AV, Manthena PV, Gearing ME, Graham MJ, Crooke RM, et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun. 2015;6:6498.<pub-id pub-id-type="pmid">25849138</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><mixed-citation publication-type="other">DiNicolantonio JJ, McCarty M, OKeefe J. Association of moderately elevated trimethylamine N-oxide with cardiovascular risk: is TMAO serving as a marker for hepatic insulin resistance. Arch Dis Childhood; 2019;6:e000890.</mixed-citation></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name></person-group><article-title>Relationship between dietary choline intake and diabetes mellitus in the National Health and Nutrition Examination Survey 2007-2010</article-title><source>J Diabetes</source><year>2021</year><volume>13</volume><fpage>554</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.13143</pub-id><pub-id pub-id-type="pmid">33301237</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Zhou L, Li X, Li S, Wen X, Peng Y, Zhao L. Relationship between dietary choline intake and diabetes mellitus in the National Health and Nutrition Examination Survey 2007-2010. J Diabetes. 2021;13:554&#x02013;61.<pub-id pub-id-type="pmid">33301237</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>CM</given-names></name><name><surname>Pacheco</surname><given-names>LS</given-names></name><name><surname>Rivas-Tumanyan</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Haslam</surname><given-names>DE</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Association of gut microbiota-related metabolites and type 2 diabetes in two Puerto Rican cohorts</article-title><source>Nutrients</source><year>2024</year><volume>16</volume><fpage>959</fpage><pub-id pub-id-type="doi">10.3390/nu16070959</pub-id><pub-id pub-id-type="pmid">38612993</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Sawicki CM, Pacheco LS, Rivas-Tumanyan S, Cao Z, Haslam DE, Liang L, et al. Association of gut microbiota-related metabolites and type 2 diabetes in two Puerto Rican cohorts. Nutrients. 2024;16:959.<pub-id pub-id-type="pmid">38612993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>ND</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name></person-group><article-title>Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention</article-title><source>Nat Rev Cardiol</source><year>2023</year><volume>20</volume><fpage>685</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/s41569-023-00877-z</pub-id><pub-id pub-id-type="pmid">37193856</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20:685&#x02013;95.<pub-id pub-id-type="pmid">37193856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gut microbiota&#x02013;derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis</article-title><source>Am J Clin Nutr</source><year>2022</year><volume>116</volume><fpage>230</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqac074</pub-id><pub-id pub-id-type="pmid">35348578</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Li D, Lu Y, Yuan S, Cai X, He Y, Chen J, et al. Gut microbiota&#x02013;derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. Am J Clin Nutr. 2022;116:230&#x02013;43.<pub-id pub-id-type="pmid">35348578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J-M</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X-H</given-names></name><name><surname>Xie</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>X-Y</given-names></name><name><surname>Ma</surname><given-names>Y-L</given-names></name></person-group><article-title>Relationship between trimethylamine N-oxide and the risk of hypertension in patients with cardiovascular disease: a meta-analysis and dose-response relationship analysis</article-title><source>Medicine</source><year>2024</year><volume>103</volume><fpage>e36784</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000036784</pub-id><pub-id pub-id-type="pmid">38181288</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Han J-M, Guo L, Chen X-H, Xie Q, Song X-Y, Ma Y-L. Relationship between trimethylamine N-oxide and the risk of hypertension in patients with cardiovascular disease: a meta-analysis and dose-response relationship analysis. Medicine. 2024;103:e36784.<pub-id pub-id-type="pmid">38181288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Guerrero</surname><given-names>JL</given-names></name><name><surname>van Dijk</surname><given-names>PR</given-names></name><name><surname>Connelly</surname><given-names>MA</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Bilo</surname><given-names>HJ</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Circulating trimethylamine N-oxide is associated with increased risk of cardiovascular mortality in type-2 diabetes: Results from a Dutch Diabetes Cohort (ZODIAC-59)</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>2269</fpage><pub-id pub-id-type="doi">10.3390/jcm10112269</pub-id><pub-id pub-id-type="pmid">34073908</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Flores-Guerrero JL, van Dijk PR, Connelly MA, Garcia E, Bilo HJ, Navis G, et al. Circulating trimethylamine N-oxide is associated with increased risk of cardiovascular mortality in type-2 diabetes: Results from a Dutch Diabetes Cohort (ZODIAC-59). J Clin Med. 2021;10:2269.<pub-id pub-id-type="pmid">34073908</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Sapa</surname><given-names>H</given-names></name><name><surname>Guti&#x000e9;rrez</surname><given-names>OM</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Ix</surname><given-names>JH</given-names></name><name><surname>Sarnak</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Association of uremic solutes with cardiovascular death in diabetic kidney disease</article-title><source>Am J Kidney Dis</source><year>2022</year><volume>80</volume><fpage>502</fpage><lpage>12.e1</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2022.02.016</pub-id><pub-id pub-id-type="pmid">35351578</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Sapa H, Guti&#x000e9;rrez OM, Shlipak MG, Katz R, Ix JH, Sarnak MJ, et al. Association of uremic solutes with cardiovascular death in diabetic kidney disease. Am J Kidney Dis. 2022;80:502&#x02013;12.e1.<pub-id pub-id-type="pmid">35351578</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Croyal</surname><given-names>M</given-names></name><name><surname>Saulnier</surname><given-names>P-J</given-names></name><name><surname>Aguesse</surname><given-names>A</given-names></name><name><surname>Gand</surname><given-names>E</given-names></name><name><surname>Ragot</surname><given-names>S</given-names></name><name><surname>Roussel</surname><given-names>R</given-names></name><etal/></person-group><article-title>Plasma trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2020</year><volume>105</volume><fpage>2371</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1210/clinem/dgaa188</pub-id></element-citation><mixed-citation id="mc-CR84" publication-type="journal">Croyal M, Saulnier P-J, Aguesse A, Gand E, Ragot S, Roussel R, et al. Plasma trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 diabetes. J Clin Endocrinol Metab. 2020;105:2371&#x02013;80.</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><mixed-citation publication-type="other">Yu P-S, Wu P-H, Hung W-W, Lin M-Y, Zhen Y-Y, Hung W-C, et al. Association between trimethylamine N-oxide and adverse kidney outcomes and overall mortality in type 2 diabetes mellitus. J Clin Endocrinol Metabol. 2024;109:dgae009.</mixed-citation></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Eyileten</surname><given-names>C</given-names></name><name><surname>Jarosz-Popek</surname><given-names>J</given-names></name><name><surname>Jakubik</surname><given-names>D</given-names></name><name><surname>Gasecka</surname><given-names>A</given-names></name><name><surname>Wolska</surname><given-names>M</given-names></name><name><surname>Ufnal</surname><given-names>M</given-names></name><etal/></person-group><article-title>Plasma trimethylamine-N-oxide is an independent predictor of long-term cardiovascular mortality in patients undergoing percutaneous coronary intervention for acute coronary syndrome</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>728724</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2021.728724</pub-id><pub-id pub-id-type="pmid">34778397</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Eyileten C, Jarosz-Popek J, Jakubik D, Gasecka A, Wolska M, Ufnal M, et al. Plasma trimethylamine-N-oxide is an independent predictor of long-term cardiovascular mortality in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Front Cardiovasc Med. 2021;8:728724.<pub-id pub-id-type="pmid">34778397</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>Circulating trimethylamine N-oxide is correlated with high coronary artery atherosclerotic burden in individuals with newly diagnosed coronary heart disease</article-title><source>BMC Cardiovasc Disord</source><year>2024</year><volume>24</volume><fpage>265</fpage><pub-id pub-id-type="doi">10.1186/s12872-024-03937-5</pub-id><pub-id pub-id-type="pmid">38773380</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Bao M, Li H, Li J. Circulating trimethylamine N-oxide is correlated with high coronary artery atherosclerotic burden in individuals with newly diagnosed coronary heart disease. BMC Cardiovasc Disord. 2024;24:265.<pub-id pub-id-type="pmid">38773380</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Dou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name></person-group><article-title>Association of trimethylamine-N-oxide levels with risk of cardiovascular disease and mortality among elderly subjects: A systematic review and meta-analysis</article-title><source>Cardiorenal Med</source><year>2022</year><volume>12</volume><fpage>39</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1159/000520910</pub-id><pub-id pub-id-type="pmid">34915483</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Chen G, He L, Dou X, Liu T. Association of trimethylamine-N-oxide levels with risk of cardiovascular disease and mortality among elderly subjects: A systematic review and meta-analysis. Cardiorenal Med. 2022;12:39&#x02013;54.<pub-id pub-id-type="pmid">34915483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Cardona</surname><given-names>A</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>A</given-names></name><name><surname>Bernier</surname><given-names>MC</given-names></name><name><surname>Somogyi</surname><given-names>A</given-names></name><name><surname>Wysocki</surname><given-names>VH</given-names></name><name><surname>Smart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis</article-title><source>BMJ Open Diabetes Res Care</source><year>2019</year><volume>7</volume><fpage>e000718</fpage><pub-id pub-id-type="doi">10.1136/bmjdrc-2019-000718</pub-id><pub-id pub-id-type="pmid">31798892</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Cardona A, O&#x02019;Brien A, Bernier MC, Somogyi A, Wysocki VH, Smart S, et al. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Res Care. 2019;7:e000718.<pub-id pub-id-type="pmid">31798892</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Schrauben</surname><given-names>SJ</given-names></name><name><surname>Sapa</surname><given-names>H</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Anderson</surname><given-names>AH</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study</article-title><source>Nephrol Dial Transplant</source><year>2023</year><volume>38</volume><fpage>2809</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfad103</pub-id><pub-id pub-id-type="pmid">37230949</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Schrauben SJ, Sapa H, Xie D, Zhang X, Anderson AH, Shlipak MG, et al. Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Nephrol Dial Transplant. 2023;38:2809&#x02013;15.<pub-id pub-id-type="pmid">37230949</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Yu N, Gu N, Wang Y, Zhou B, Lu D, Li J, et al. The association of plasma trimethylamine N-oxide with coronary atherosclerotic burden in patients with type 2 diabetes among a Chinese north population. Diabetes Metab Syndr Obes. 2022;15:69&#x02013;78.</mixed-citation></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Winther</surname><given-names>SA</given-names></name><name><surname>&#x000d8;llgaard</surname><given-names>JC</given-names></name><name><surname>Hansen</surname><given-names>TW</given-names></name><name><surname>Von Scholten</surname><given-names>BJ</given-names></name><name><surname>Reinhard</surname><given-names>H</given-names></name><name><surname>Ahluwalia</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><fpage>e0244402</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0244402</pub-id><pub-id pub-id-type="pmid">33657115</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Winther SA, &#x000d8;llgaard JC, Hansen TW, Von Scholten BJ, Reinhard H, Ahluwalia TS, et al. Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. PLoS One. 2021;16:e0244402.<pub-id pub-id-type="pmid">33657115</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><citation-alternatives><element-citation id="ec-CR93" publication-type="journal"><person-group person-group-type="author"><name><surname>Kalagi</surname><given-names>NA</given-names></name><name><surname>Thota</surname><given-names>RN</given-names></name><name><surname>Stojanovski</surname><given-names>E</given-names></name><name><surname>Alburikan</surname><given-names>KA</given-names></name><name><surname>Garg</surname><given-names>ML</given-names></name></person-group><article-title>Plasma trimethylamine N-oxide levels are associated with poor kidney function in people with type 2 diabetes</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><fpage>812</fpage><pub-id pub-id-type="doi">10.3390/nu15040812</pub-id><pub-id pub-id-type="pmid">36839170</pub-id>
</element-citation><mixed-citation id="mc-CR93" publication-type="journal">Kalagi NA, Thota RN, Stojanovski E, Alburikan KA, Garg ML. Plasma trimethylamine N-oxide levels are associated with poor kidney function in people with type 2 diabetes. Nutrients. 2023;15:812.<pub-id pub-id-type="pmid">36839170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR94"><label>94.</label><mixed-citation publication-type="other">Huang Y, Zhu Z, Huang Z, Zhou J. Elevated serum trimethylamine oxide levels as potential biomarker for diabetic kidney disease. Endocrine Connections. 2023;12:e220542.</mixed-citation></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Wargny</surname><given-names>M</given-names></name><name><surname>Croyal</surname><given-names>M</given-names></name><name><surname>Ragot</surname><given-names>S</given-names></name><name><surname>Gand</surname><given-names>E</given-names></name><name><surname>Jacobi</surname><given-names>D</given-names></name><name><surname>Trochu</surname><given-names>J-N</given-names></name><etal/></person-group><article-title>Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort</article-title><source>Cardiovasc Diabetol</source><year>2022</year><volume>21</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s12933-022-01505-9</pub-id><pub-id pub-id-type="pmid">35681209</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Wargny M, Croyal M, Ragot S, Gand E, Jacobi D, Trochu J-N, et al. Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort. Cardiovasc Diabetol. 2022;21:101.<pub-id pub-id-type="pmid">35681209</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Winther</surname><given-names>SA</given-names></name><name><surname>&#x000d8;llgaard</surname><given-names>JC</given-names></name><name><surname>Tofte</surname><given-names>N</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Ahluwalia</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Utility of plasma concentration of trimethylamine N-oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes</article-title><source>Diabetes care</source><year>2019</year><volume>42</volume><fpage>1512</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2337/dc19-0048</pub-id><pub-id pub-id-type="pmid">31123156</pub-id>
</element-citation><mixed-citation id="mc-CR96" publication-type="journal">Winther SA, &#x000d8;llgaard JC, Tofte N, Tarnow L, Wang Z, Ahluwalia TS, et al. Utility of plasma concentration of trimethylamine N-oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes. Diabetes care. 2019;42:1512&#x02013;20.<pub-id pub-id-type="pmid">31123156</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Yakar</surname><given-names>B</given-names></name><name><surname>Onalan</surname><given-names>E</given-names></name><name><surname>Kaymaz</surname><given-names>T</given-names></name><name><surname>Donder</surname><given-names>E</given-names></name><name><surname>Gursu</surname><given-names>MF</given-names></name></person-group><article-title>The role of trimethylamine-N-oxide level in the diagnosis of diabetic retinopathy and the differential diagnosis of diabetic and nondiabetic retinopathy</article-title><source>Arquivos Brasileiros de Oftalmologia</source><year>2022</year><volume>87</volume><fpage>e2021</fpage><lpage>0527</lpage><pub-id pub-id-type="doi">10.5935/0004-2749.2021-0527</pub-id><pub-id pub-id-type="pmid">36350906</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Yakar B, Onalan E, Kaymaz T, Donder E, Gursu MF. The role of trimethylamine-N-oxide level in the diagnosis of diabetic retinopathy and the differential diagnosis of diabetic and nondiabetic retinopathy. Arquivos Brasileiros de Oftalmologia. 2022;87:e2021&#x02013;0527.<pub-id pub-id-type="pmid">36350906</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Ren</surname><given-names>C</given-names></name><etal/></person-group><article-title>Elevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy</article-title><source>Acta Diabetologica</source><year>2021</year><volume>58</volume><fpage>221</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1007/s00592-020-01610-9</pub-id><pub-id pub-id-type="pmid">33064205</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Liu W, Wang C, Xia Y, Xia W, Liu G, Ren C, et al. Elevated plasma trimethylamine-N-oxide levels are associated with diabetic retinopathy. Acta Diabetologica. 2021;58:221&#x02013;9.<pub-id pub-id-type="pmid">33064205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name></person-group><article-title>Trimethylamine-N-Oxide Promotes High-Glucose-Induced Dysfunction and NLRP3 Inflammasome Activation in Retinal Microvascular Endothelial Cells</article-title><source>J Ophthalmol</source><year>2023</year><volume>2023</volume><fpage>8224752</fpage><pub-id pub-id-type="doi">10.1155/2023/8224752</pub-id><pub-id pub-id-type="pmid">36895266</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Xue L, Huang L, Tian Y, Cao X, Song Y. Trimethylamine-N-Oxide Promotes High-Glucose-Induced Dysfunction and NLRP3 Inflammasome Activation in Retinal Microvascular Endothelial Cells. J Ophthalmol. 2023;2023:8224752.<pub-id pub-id-type="pmid">36895266</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><citation-alternatives><element-citation id="ec-CR100" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide predicts stroke severity in diabetic patients with acute ischaemic stroke and is related to glycemic variability</article-title><source>Eur J Neurol</source><year>2023</year><volume>30</volume><fpage>3478</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/ene.15249</pub-id><pub-id pub-id-type="pmid">35020253</pub-id>
</element-citation><mixed-citation id="mc-CR100" publication-type="journal">Li Z, Hui J, Li S, Cao T, Zhang J, Mao X, et al. Trimethylamine N-oxide predicts stroke severity in diabetic patients with acute ischaemic stroke and is related to glycemic variability. Eur J Neurol. 2023;30:3478&#x02013;86.<pub-id pub-id-type="pmid">35020253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR101"><label>101.</label><mixed-citation publication-type="other">Xu N, Wan J, Wang C, Liu J, Qian C, Tan H. Increased serum trimethylamine n-oxide level in type 2 diabetic patients with mild cognitive impairment. Diabetes Metab Syndr Obes. 2022;15:2197&#x02013;205.</mixed-citation></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Yuan Y, Gan C, Wang M, Zou J, Wang Z, Li S, et al. Association of serum trimethylamine N-oxide levels and bone mineral density in type 2 diabetes mellitus. Endocrine. 2024;84:1&#x02013;11.</mixed-citation></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Heianza</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>DiDonato</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Circulating gut microbiota metabolite trimethylamine N-oxide (TMAO) and changes in bone density in response to weight loss diets: the POUNDS lost trial</article-title><source>Diabetes Care</source><year>2019</year><volume>42</volume><fpage>1365</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.2337/dc19-0134</pub-id><pub-id pub-id-type="pmid">31332027</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Zhou T, Heianza Y, Chen Y, Li X, Sun D, DiDonato JA, et al. Circulating gut microbiota metabolite trimethylamine N-oxide (TMAO) and changes in bone density in response to weight loss diets: the POUNDS lost trial. Diabetes Care. 2019;42:1365&#x02013;71.<pub-id pub-id-type="pmid">31332027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuka</surname><given-names>J</given-names></name><name><surname>Videja</surname><given-names>M</given-names></name><name><surname>Makrecka-Kuka</surname><given-names>M</given-names></name><name><surname>Liepins</surname><given-names>J</given-names></name><name><surname>Grinberga</surname><given-names>S</given-names></name><name><surname>Sevostjanovs</surname><given-names>E</given-names></name><etal/></person-group><article-title>Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><fpage>14555</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-71470-4</pub-id><pub-id pub-id-type="pmid">32884086</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Kuka J, Videja M, Makrecka-Kuka M, Liepins J, Grinberga S, Sevostjanovs E, et al. Metformin decreases bacterial trimethylamine production and trimethylamine N-oxide levels in db/db mice. Sci Rep. 2020;10:14555.<pub-id pub-id-type="pmid">32884086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality</article-title><source>Nutr Diabetes</source><year>2021</year><volume>11</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1038/s41387-021-00169-w</pub-id><pub-id pub-id-type="pmid">34389700</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Su C, Li X, Yang Y, Du Y, Zhang X, Wang L, et al. Metformin alleviates choline diet-induced TMAO elevation in C57BL/6J mice by influencing gut-microbiota composition and functionality. Nutr Diabetes. 2021;11:27.<pub-id pub-id-type="pmid">34389700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><mixed-citation publication-type="other">Canyelles M, P&#x000e9;rez A, Junza A, Mi&#x000f1;ambres I, Yanes O, Sard&#x000e0; H, et al. Divergent effects of glycemic control and bariatric surgery on circulating concentrations of TMAO in newly diagnosed T2D patients and morbidly obese. Diagnostics. 2022;12:2783.</mixed-citation></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Sha</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride</article-title><source>J Pharm Biomed Anal</source><year>2009</year><volume>49</volume><fpage>976</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2009.01.008</pub-id><pub-id pub-id-type="pmid">19249171</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Huo T, Cai S, Lu X, Sha Y, Yu M, Li F. Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal. 2009;49:976&#x02013;82.<pub-id pub-id-type="pmid">19249171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TT</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name></person-group><article-title>Direct CCL4 inhibition modulates gut microbiota, reduces circulating trimethylamine N-Oxide, and improves glucose and lipid metabolism in high-fat-diet-induced diabetes mellitus</article-title><source>J Inflamm Res</source><year>2021</year><volume>14</volume><fpage>6237</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.2147/JIR.S343491</pub-id><pub-id pub-id-type="pmid">34866923</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Chang TT, Chen JW. Direct CCL4 inhibition modulates gut microbiota, reduces circulating trimethylamine N-Oxide, and improves glucose and lipid metabolism in high-fat-diet-induced diabetes mellitus. J Inflamm Res. 2021;14:6237&#x02013;50.<pub-id pub-id-type="pmid">34866923</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Shyshkan-Shyshova</surname><given-names>KO</given-names></name><name><surname>Zinych</surname><given-names>OV</given-names></name><name><surname>&#x0041a;ushnareva</surname><given-names>NM</given-names></name><name><surname>&#x0041a;ovalchuk</surname><given-names>AV</given-names></name><name><surname>Prybyla</surname><given-names>&#x0041e;V</given-names></name></person-group><article-title>The effects of incretin mimetics on the level of the microbial metabolite trimethylamine-N-oxide, a marker of cardiovascular risk in type 2 diabetic patients</article-title><source>Int J Endocrinol</source><year>2023</year><volume>19</volume><fpage>523</fpage><lpage>8</lpage></element-citation><mixed-citation id="mc-CR109" publication-type="journal">Shyshkan-Shyshova KO, Zinych OV, &#x0041a;ushnareva NM, &#x0041a;ovalchuk AV, Prybyla &#x0041e;V. The effects of incretin mimetics on the level of the microbial metabolite trimethylamine-N-oxide, a marker of cardiovascular risk in type 2 diabetic patients. Int J Endocrinol. 2023;19:523&#x02013;8.</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>Effect of dapagliflozin on ferroptosis through the gut microbiota metabolite TMAO during myocardial ischemia-reperfusion injury in diabetes mellitus rats</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><fpage>13851</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-64909-5</pub-id><pub-id pub-id-type="pmid">38879701</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Wang L, Wang Y, Xu H, Li W. Effect of dapagliflozin on ferroptosis through the gut microbiota metabolite TMAO during myocardial ischemia-reperfusion injury in diabetes mellitus rats. Sci Rep. 2024;14:13851.<pub-id pub-id-type="pmid">38879701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>F</given-names></name><name><surname>Tripolt</surname><given-names>NJ</given-names></name><name><surname>Pferschy</surname><given-names>PN</given-names></name><name><surname>Kolesnik</surname><given-names>E</given-names></name><name><surname>Mangge</surname><given-names>H</given-names></name><name><surname>Curcic</surname><given-names>P</given-names></name><etal/></person-group><article-title>Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial</article-title><source>Cardiovasc Diabetol</source><year>2023</year><volume>22</volume><fpage>184</fpage><pub-id pub-id-type="doi">10.1186/s12933-023-01920-6</pub-id><pub-id pub-id-type="pmid">37475009</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Aziz F, Tripolt NJ, Pferschy PN, Kolesnik E, Mangge H, Curcic P, et al. Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial. Cardiovasc Diabetol. 2023;22:184.<pub-id pub-id-type="pmid">37475009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><citation-alternatives><element-citation id="ec-CR112" publication-type="journal"><person-group person-group-type="author"><name><surname>Kwee</surname><given-names>LC</given-names></name><name><surname>Ilkayeva</surname><given-names>O</given-names></name><name><surname>Muehlbauer</surname><given-names>MJ</given-names></name><name><surname>Bihlmeyer</surname><given-names>N</given-names></name><name><surname>Wolfe</surname><given-names>B</given-names></name><name><surname>Purnell</surname><given-names>JQ</given-names></name><etal/></person-group><article-title>Metabolites and diabetes remission after weight loss</article-title><source>Nutr Diabetes</source><year>2021</year><volume>11</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1038/s41387-021-00151-6</pub-id><pub-id pub-id-type="pmid">33627633</pub-id>
</element-citation><mixed-citation id="mc-CR112" publication-type="journal">Kwee LC, Ilkayeva O, Muehlbauer MJ, Bihlmeyer N, Wolfe B, Purnell JQ, et al. Metabolites and diabetes remission after weight loss. Nutr Diabetes. 2021;11:10.<pub-id pub-id-type="pmid">33627633</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Argyridou</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Biddle</surname><given-names>GJH</given-names></name><name><surname>Bernieh</surname><given-names>D</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Dawkins</surname><given-names>NP</given-names></name><etal/></person-group><article-title>Evaluation of an 8-Week Vegan Diet on Plasma Trimethylamine-N-Oxide and Postchallenge Glucose in Adults with Dysglycemia or Obesity</article-title><source>J Nutr</source><year>2021</year><volume>151</volume><fpage>1844</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1093/jn/nxab046</pub-id><pub-id pub-id-type="pmid">33784394</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Argyridou S, Davies MJ, Biddle GJH, Bernieh D, Suzuki T, Dawkins NP, et al. Evaluation of an 8-Week Vegan Diet on Plasma Trimethylamine-N-Oxide and Postchallenge Glucose in Adults with Dysglycemia or Obesity. J Nutr. 2021;151:1844&#x02013;53.<pub-id pub-id-type="pmid">33784394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Heianza</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>DiDonato</surname><given-names>JA</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>Sacks</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial</article-title><source>Gut</source><year>2019</year><volume>68</volume><fpage>263</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2018-316155</pub-id><pub-id pub-id-type="pmid">29860242</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Heianza Y, Sun D, Li X, DiDonato JA, Bray GA, Sacks FM, et al. Gut microbiota metabolites, amino acid metabolites and improvements in insulin sensitivity and glucose metabolism: the POUNDS Lost trial. Gut. 2019;68:263&#x02013;70.<pub-id pub-id-type="pmid">29860242</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Costabile</surname><given-names>G</given-names></name><name><surname>Vetrani</surname><given-names>C</given-names></name><name><surname>Bozzetto</surname><given-names>L</given-names></name><name><surname>Giacco</surname><given-names>R</given-names></name><name><surname>Bresciani</surname><given-names>L</given-names></name><name><surname>Del Rio</surname><given-names>D</given-names></name><etal/></person-group><article-title>Plasma TMAO increase after healthy diets: results from 2 randomized controlled trials with dietary fish, polyphenols, and whole-grain cereals</article-title><source>Am J Clin Nutr</source><year>2021</year><volume>114</volume><fpage>1342</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/ajcn/nqab188</pub-id><pub-id pub-id-type="pmid">34091663</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Costabile G, Vetrani C, Bozzetto L, Giacco R, Bresciani L, Del Rio D, et al. Plasma TMAO increase after healthy diets: results from 2 randomized controlled trials with dietary fish, polyphenols, and whole-grain cereals. Am J Clin Nutr. 2021;114:1342&#x02013;50.<pub-id pub-id-type="pmid">34091663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>CE</given-names></name><name><surname>Taesuwan</surname><given-names>S</given-names></name><name><surname>Malysheva</surname><given-names>OV</given-names></name><name><surname>Bender</surname><given-names>E</given-names></name><name><surname>Tulchinsky</surname><given-names>NF</given-names></name><name><surname>Yan</surname><given-names>J</given-names></name><etal/></person-group><article-title>Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial</article-title><source>Mol Nutr Food Res</source><year>2017</year><volume>61</volume><fpage>1600324</fpage><pub-id pub-id-type="doi">10.1002/mnfr.201600324</pub-id></element-citation><mixed-citation id="mc-CR116" publication-type="journal">Cho CE, Taesuwan S, Malysheva OV, Bender E, Tulchinsky NF, Yan J, et al. Trimethylamine-N-oxide (TMAO) response to animal source foods varies among healthy young men and is influenced by their gut microbiota composition: a randomized controlled trial. Mol Nutr Food Res. 2017;61:1600324.</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Troseid</surname><given-names>M</given-names></name><name><surname>Hov</surname><given-names>JR</given-names></name><name><surname>Nestvold</surname><given-names>TK</given-names></name><name><surname>Thoresen</surname><given-names>H</given-names></name><name><surname>Berge</surname><given-names>RK</given-names></name><name><surname>Svardal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery</article-title><source>Metab Syndr Relat Disord</source><year>2016</year><volume>14</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1089/met.2015.0120</pub-id><pub-id pub-id-type="pmid">27081744</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Troseid M, Hov JR, Nestvold TK, Thoresen H, Berge RK, Svardal A, et al. Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery. Metab Syndr Relat Disord. 2016;14:197&#x02013;201.<pub-id pub-id-type="pmid">27081744</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>S</given-names></name><name><surname>Gertz</surname><given-names>ER</given-names></name><name><surname>Adams</surname><given-names>SH</given-names></name><name><surname>Newman</surname><given-names>JW</given-names></name><name><surname>Pedersen</surname><given-names>TL</given-names></name><name><surname>Keim</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Effects of a diet based on the Dietary Guidelines on vascular health and TMAO in women with cardiometabolic risk factors</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2022</year><volume>32</volume><fpage>210</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2021.09.013</pub-id><pub-id pub-id-type="pmid">34895998</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">Krishnan S, Gertz ER, Adams SH, Newman JW, Pedersen TL, Keim NL, et al. Effects of a diet based on the Dietary Guidelines on vascular health and TMAO in women with cardiometabolic risk factors. Nutr Metab Cardiovasc Dis. 2022;32:210&#x02013;9.<pub-id pub-id-type="pmid">34895998</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Cash</surname><given-names>JG</given-names></name><name><surname>Konaniah</surname><given-names>E</given-names></name><name><surname>Hegde</surname><given-names>N</given-names></name><name><surname>Kuhel</surname><given-names>DG</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Romick-Rosendale</surname><given-names>L</given-names></name><etal/></person-group><article-title>Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission</article-title><source>Mol Metab</source><year>2018</year><volume>16</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.molmet.2018.07.009</pub-id><pub-id pub-id-type="pmid">30087032</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Cash JG, Konaniah E, Hegde N, Kuhel DG, Watanabe M, Romick-Rosendale L, et al. Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission. Mol Metab. 2018;16:55&#x02013;64.<pub-id pub-id-type="pmid">30087032</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><mixed-citation publication-type="other">Lee SJ, Park YS, Kim YJ, Han SU, Hwang GS, Han Y, et al. Changes in trimethylamine-N-oxide levels in obese patients following laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy in a Korean obesity surgical treatment study (KOBESS). J Clin Med. 2021;10:5091.</mixed-citation></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide exacerbates renal inflammation and fibrosis in rats with diabetic kidney disease</article-title><source>Front Physiol</source><year>2021</year><volume>12</volume><fpage>682482</fpage><pub-id pub-id-type="doi">10.3389/fphys.2021.682482</pub-id><pub-id pub-id-type="pmid">34220546</pub-id>
</element-citation><mixed-citation id="mc-CR121" publication-type="journal">Fang Q, Zheng B, Liu N, Liu J, Liu W, Huang X, et al. Trimethylamine N-oxide exacerbates renal inflammation and fibrosis in rats with diabetic kidney disease. Front Physiol. 2021;12:682482.<pub-id pub-id-type="pmid">34220546</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J-Y</given-names></name><name><surname>Liu</surname><given-names>W-M</given-names></name><name><surname>Zhang</surname><given-names>Q-P</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Yao</surname><given-names>Q-Y</given-names></name><name><surname>Liu</surname><given-names>G-Q</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide aggravates vascular permeability and endothelial cell dysfunction under diabetic condition: in vitro and in vivo study</article-title><source>Int J Ophthalmol</source><year>2024</year><volume>17</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.18240/ijo.2024.01.04</pub-id><pub-id pub-id-type="pmid">38239938</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Jiang J-Y, Liu W-M, Zhang Q-P, Ren H, Yao Q-Y, Liu G-Q, et al. Trimethylamine N-oxide aggravates vascular permeability and endothelial cell dysfunction under diabetic condition: in vitro and in vivo study. Int J Ophthalmol. 2024;17:25.<pub-id pub-id-type="pmid">38239938</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet</article-title><source>J Biosci Bioeng</source><year>2014</year><volume>118</volume><fpage>476</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jbiosc.2014.03.001</pub-id><pub-id pub-id-type="pmid">24721123</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Gao X, Liu X, Xu J, Xue C, Xue Y, Wang Y. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014;118:476&#x02013;81.<pub-id pub-id-type="pmid">24721123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Fish oil ameliorates trimethylamine N-oxide-exacerbated glucose intolerance in high-fat diet-fed mice</article-title><source>Food Funct</source><year>2015</year><volume>6</volume><fpage>1117</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1039/C5FO00007F</pub-id><pub-id pub-id-type="pmid">25686243</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Gao X, Xu J, Jiang C, Zhang Y, Xue Y, Li Z, et al. Fish oil ameliorates trimethylamine N-oxide-exacerbated glucose intolerance in high-fat diet-fed mice. Food Funct. 2015;6:1117&#x02013;25.<pub-id pub-id-type="pmid">25686243</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Sheng</surname><given-names>L</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide impairs &#x003b2;-cell function and glucose tolerance</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><fpage>2526</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-46829-0</pub-id><pub-id pub-id-type="pmid">38514666</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Kong L, Zhao Q, Jiang X, Hu J, Jiang Q, Sheng L, et al. Trimethylamine N-oxide impairs &#x003b2;-cell function and glucose tolerance. Nat Commun. 2024;15:2526.<pub-id pub-id-type="pmid">38514666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Henderson</surname><given-names>A</given-names></name><name><surname>Petriello</surname><given-names>MC</given-names></name><name><surname>Romano</surname><given-names>KA</given-names></name><name><surname>Gearing</surname><given-names>M</given-names></name><name><surname>Miao</surname><given-names>J</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction</article-title><source>Cell Metab</source><year>2019</year><volume>30</volume><fpage>1141</fpage><lpage>51.e5</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.08.021</pub-id><pub-id pub-id-type="pmid">31543404</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Chen S, Henderson A, Petriello MC, Romano KA, Gearing M, Miao J, et al. Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab. 2019;30:1141&#x02013;51.e5.<pub-id pub-id-type="pmid">31543404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>Govindarajulu</surname><given-names>M</given-names></name><name><surname>Pinky</surname><given-names>PD</given-names></name><name><surname>Steinke</surname><given-names>I</given-names></name><name><surname>Bloemer</surname><given-names>J</given-names></name><name><surname>Ramesh</surname><given-names>S</given-names></name><name><surname>Kariharan</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gut metabolite TMAO induces synaptic plasticity deficits by promoting endoplasmic reticulum stress</article-title><source>Front Mol Neurosci</source><year>2020</year><volume>13</volume><fpage>138</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2020.00138</pub-id><pub-id pub-id-type="pmid">32903435</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">Govindarajulu M, Pinky PD, Steinke I, Bloemer J, Ramesh S, Kariharan T, et al. Gut metabolite TMAO induces synaptic plasticity deficits by promoting endoplasmic reticulum stress. Front Mol Neurosci. 2020;13:138.<pub-id pub-id-type="pmid">32903435</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y-l</given-names></name><name><surname>Xiang</surname><given-names>Q</given-names></name><name><surname>Zou</surname><given-names>J-j</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name></person-group><article-title>Zuogui Jiangtang Shuxin formula Ameliorates diabetic cardiomyopathy mice via modulating gut-heart axis</article-title><source>Front Endocrinol</source><year>2023</year><volume>14</volume><fpage>1106812</fpage><pub-id pub-id-type="doi">10.3389/fendo.2023.1106812</pub-id></element-citation><mixed-citation id="mc-CR128" publication-type="journal">Huang Y-l, Xiang Q, Zou J-j, Wu Y, Yu R. Zuogui Jiangtang Shuxin formula Ameliorates diabetic cardiomyopathy mice via modulating gut-heart axis. Front Endocrinol. 2023;14:1106812.</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><citation-alternatives><element-citation id="ec-CR129" publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>M-E</given-names></name><name><surname>Rothwell</surname><given-names>AR</given-names></name><name><surname>Hoyles</surname><given-names>L</given-names></name><name><surname>Aranias</surname><given-names>T</given-names></name><name><surname>Chilloux</surname><given-names>J</given-names></name><name><surname>Calderari</surname><given-names>S</given-names></name><etal/></person-group><article-title>Microbial-host co-metabolites are prodromal markers predicting phenotypic heterogeneity in behavior, obesity, and impaired glucose tolerance</article-title><source>Cell Rep</source><year>2017</year><volume>20</volume><fpage>136</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.06.039</pub-id><pub-id pub-id-type="pmid">28683308</pub-id>
</element-citation><mixed-citation id="mc-CR129" publication-type="journal">Dumas M-E, Rothwell AR, Hoyles L, Aranias T, Chilloux J, Calderari S, et al. Microbial-host co-metabolites are prodromal markers predicting phenotypic heterogeneity in behavior, obesity, and impaired glucose tolerance. Cell Rep. 2017;20:136&#x02013;48.<pub-id pub-id-type="pmid">28683308</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>C</given-names></name><name><surname>Biwersi</surname><given-names>J</given-names></name><name><surname>Verkman</surname><given-names>A</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>A mouse model to test the in vivo efficacy of chemical chaperones</article-title><source>J Pharmacol Toxicological methods</source><year>1998</year><volume>40</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S1056-8719(98)00034-3</pub-id></element-citation><mixed-citation id="mc-CR130" publication-type="journal">Bai C, Biwersi J, Verkman A, Matthay MA. A mouse model to test the in vivo efficacy of chemical chaperones. J Pharmacol Toxicological methods. 1998;40:39&#x02013;45.</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Akerfeldt</surname><given-names>MC</given-names></name><name><surname>Howes</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>JY</given-names></name><name><surname>Stevens</surname><given-names>VA</given-names></name><name><surname>Boubenna</surname><given-names>N</given-names></name><name><surname>McGuire</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Cytokine-induced &#x003b2;-cell death is independent of endoplasmic reticulum stress signaling</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>3034</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.2337/db07-1802</pub-id><pub-id pub-id-type="pmid">18591394</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Akerfeldt MC, Howes J, Chan JY, Stevens VA, Boubenna N, McGuire HM, et al. Cytokine-induced &#x003b2;-cell death is independent of endoplasmic reticulum stress signaling. Diabetes. 2008;57:3034&#x02013;44.<pub-id pub-id-type="pmid">18591394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>ES</given-names></name><name><surname>Beales</surname><given-names>JL</given-names></name><name><surname>Russon</surname><given-names>KB</given-names></name><name><surname>Elison</surname><given-names>WS</given-names></name><name><surname>Davis</surname><given-names>JR</given-names></name><name><surname>Hansen</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Gut metabolite trimethylamine n-oxide protects INS-1 &#x003b2;-cell and rat islet function under diabetic glucolipotoxic conditions</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><fpage>1892</fpage><pub-id pub-id-type="doi">10.3390/biom11121892</pub-id><pub-id pub-id-type="pmid">34944536</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Krueger ES, Beales JL, Russon KB, Elison WS, Davis JR, Hansen JM, et al. Gut metabolite trimethylamine n-oxide protects INS-1 &#x003b2;-cell and rat islet function under diabetic glucolipotoxic conditions. Biomolecules. 2021;11:1892.<pub-id pub-id-type="pmid">34944536</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Achard</surname><given-names>CS</given-names></name><name><surname>Laybutt</surname><given-names>DR</given-names></name></person-group><article-title>Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance</article-title><source>Endocrinology</source><year>2012</year><volume>153</volume><fpage>2164</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1210/en.2011-1881</pub-id><pub-id pub-id-type="pmid">22374970</pub-id>
</element-citation><mixed-citation id="mc-CR133" publication-type="journal">Achard CS, Laybutt DR. Lipid-induced endoplasmic reticulum stress in liver cells results in two distinct outcomes: adaptation with enhanced insulin signaling or insulin resistance. Endocrinology. 2012;153:2164&#x02013;77.<pub-id pub-id-type="pmid">22374970</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Jahan</surname><given-names>I</given-names></name><name><surname>Nayeem</surname><given-names>SM</given-names></name></person-group><article-title>In silico studies of the human IAPP in the presence of osmolytes</article-title><source>J Mol Model</source><year>2022</year><volume>28</volume><fpage>188</fpage><pub-id pub-id-type="doi">10.1007/s00894-022-05180-1</pub-id><pub-id pub-id-type="pmid">35697975</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Khan A, Jahan I, Nayeem SM. In silico studies of the human IAPP in the presence of osmolytes. J Mol Model. 2022;28:188.<pub-id pub-id-type="pmid">35697975</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Somvanshi</surname><given-names>P</given-names></name><name><surname>Grover</surname><given-names>A</given-names></name></person-group><article-title>Assessing the role of osmolytes on the conformational harmony of islet amyloid polypeptide</article-title><source>Int J Biol Macromolecules</source><year>2020</year><volume>164</volume><fpage>2569</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.08.104</pub-id></element-citation><mixed-citation id="mc-CR135" publication-type="journal">Kumari A, Sharma R, Somvanshi P, Grover A. Assessing the role of osmolytes on the conformational harmony of islet amyloid polypeptide. Int J Biol Macromolecules. 2020;164:2569&#x02013;82.</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Lupachyk</surname><given-names>S</given-names></name><name><surname>Watcho</surname><given-names>P</given-names></name><name><surname>Stavniichuk</surname><given-names>R</given-names></name><name><surname>Shevalye</surname><given-names>H</given-names></name><name><surname>Obrosova</surname><given-names>IG</given-names></name></person-group><article-title>Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>944</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.2337/db12-0716</pub-id><pub-id pub-id-type="pmid">23364451</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Lupachyk S, Watcho P, Stavniichuk R, Shevalye H, Obrosova IG. Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy. Diabetes. 2013;62:944&#x02013;52.<pub-id pub-id-type="pmid">23364451</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>GK</given-names></name><name><surname>Ball</surname><given-names>KK</given-names></name><name><surname>Cruz</surname><given-names>NF</given-names></name><name><surname>Dienel</surname><given-names>GA</given-names></name></person-group><article-title>Hyperglycaemia and diabetes impair gap junctional communication among astrocytes</article-title><source>ASN Neuro</source><year>2010</year><volume>2</volume><fpage>AN20090048</fpage><pub-id pub-id-type="doi">10.1042/AN20090048</pub-id></element-citation><mixed-citation id="mc-CR137" publication-type="journal">Gandhi GK, Ball KK, Cruz NF, Dienel GA. Hyperglycaemia and diabetes impair gap junctional communication among astrocytes. ASN Neuro. 2010;2:AN20090048.</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>Wankeu-Nya</surname><given-names>M</given-names></name><name><surname>Watcho</surname><given-names>P</given-names></name><name><surname>Deeh Defo</surname><given-names>PB</given-names></name><name><surname>Ngadjui</surname><given-names>E</given-names></name><name><surname>Nguelefack</surname><given-names>TB</given-names></name><name><surname>Kamtchouing</surname><given-names>P</given-names></name><etal/></person-group><article-title>Aqueous and ethanol extracts of Dracaena arborea (Wild) Link (Dracaenaceae) alleviate reproductive complications of diabetes mellitus in rats</article-title><source>Andrologia</source><year>2019</year><volume>51</volume><fpage>e13381</fpage><pub-id pub-id-type="doi">10.1111/and.13381</pub-id><pub-id pub-id-type="pmid">31373720</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">Wankeu-Nya M, Watcho P, Deeh Defo PB, Ngadjui E, Nguelefack TB, Kamtchouing P, et al. Aqueous and ethanol extracts of Dracaena arborea (Wild) Link (Dracaenaceae) alleviate reproductive complications of diabetes mellitus in rats. Andrologia. 2019;51:e13381.<pub-id pub-id-type="pmid">31373720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><mixed-citation publication-type="other">Li Z, Li L, Yue M, Peng Q, Pu X, Zhou Y. Tracing immunological interaction in trimethylamine N-oxide hydrogel-derived zwitterionic microenvironment during promoted diabetic wound regeneration. Adv Mater. 2024;36:2402738.</mixed-citation></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Yu</surname><given-names>ZL</given-names></name><name><surname>Zhao</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>DD</given-names></name><name><surname>Xue</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Gut microbiota metabolite TMA may mediate the effects of TMAO on glucose and lipid metabolism in C57BL/6J mice</article-title><source>Mol Nutr Food Res</source><year>2024</year><volume>68</volume><fpage>2300443</fpage><pub-id pub-id-type="doi">10.1002/mnfr.202300443</pub-id></element-citation><mixed-citation id="mc-CR140" publication-type="journal">Li XY, Yu ZL, Zhao YC, Wang DD, Xue CH, Zhang TT, et al. Gut microbiota metabolite TMA may mediate the effects of TMAO on glucose and lipid metabolism in C57BL/6J mice. Mol Nutr Food Res. 2024;68:2300443.</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Lanz</surname><given-names>M</given-names></name><name><surname>Janeiro</surname><given-names>MH</given-names></name><name><surname>Milagro</surname><given-names>FI</given-names></name><name><surname>Puerta</surname><given-names>E</given-names></name><name><surname>Ludwig</surname><given-names>IA</given-names></name><name><surname>Pineda-Lucena</surname><given-names>A</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model</article-title><source>Mechanisms Ageing Dev</source><year>2022</year><volume>204</volume><fpage>111668</fpage><pub-id pub-id-type="doi">10.1016/j.mad.2022.111668</pub-id></element-citation><mixed-citation id="mc-CR141" publication-type="journal">Lanz M, Janeiro MH, Milagro FI, Puerta E, Ludwig IA, Pineda-Lucena A, et al. Trimethylamine N-oxide (TMAO) drives insulin resistance and cognitive deficiencies in a senescence accelerated mouse model. Mechanisms Ageing Dev. 2022;204:111668.</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W-Y</given-names></name><name><surname>Huo</surname><given-names>J-Y</given-names></name><name><surname>Wang</surname><given-names>S-C</given-names></name><name><surname>Cheng</surname><given-names>Y-D</given-names></name><name><surname>Lyu</surname><given-names>Y-T</given-names></name><name><surname>Jiang</surname><given-names>Z-X</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide facilitates the progression of atrial fibrillation in rats with type 2 diabetes by aggravating cardiac inflammation and connexin remodeling</article-title><source>J Physiol Biochem</source><year>2022</year><volume>78</volume><fpage>855</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1007/s13105-022-00908-2</pub-id><pub-id pub-id-type="pmid">35962903</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Jiang W-Y, Huo J-Y, Wang S-C, Cheng Y-D, Lyu Y-T, Jiang Z-X, et al. Trimethylamine N-oxide facilitates the progression of atrial fibrillation in rats with type 2 diabetes by aggravating cardiac inflammation and connexin remodeling. J Physiol Biochem. 2022;78:855&#x02013;67.<pub-id pub-id-type="pmid">35962903</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Andraos</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Lange</surname><given-names>K</given-names></name><name><surname>Clifford</surname><given-names>SA</given-names></name><name><surname>Thorstensen</surname><given-names>EB</given-names></name><name><surname>Kerr</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Trimethylamine N-oxide (TMAO) is not associated with cardiometabolic phenotypes and inflammatory markers in children and adults</article-title><source>Current Dev Nutr</source><year>2021</year><volume>5</volume><fpage>nzaa179</fpage><pub-id pub-id-type="doi">10.1093/cdn/nzaa179</pub-id></element-citation><mixed-citation id="mc-CR143" publication-type="journal">Andraos S, Jones B, Lange K, Clifford SA, Thorstensen EB, Kerr JA, et al. Trimethylamine N-oxide (TMAO) is not associated with cardiometabolic phenotypes and inflammatory markers in children and adults. Current Dev Nutr. 2021;5:nzaa179.</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Jaworska</surname><given-names>K</given-names></name><name><surname>Bielinska</surname><given-names>K</given-names></name><name><surname>Gawrys-Kopczynska</surname><given-names>M</given-names></name><name><surname>Ufnal</surname><given-names>M</given-names></name></person-group><article-title>TMA (trimethylamine), but not its oxide TMAO (trimethylamine-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome</article-title><source>Cardiovasc Res</source><year>2019</year><volume>115</volume><fpage>1948</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvz231</pub-id><pub-id pub-id-type="pmid">31504256</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Jaworska K, Bielinska K, Gawrys-Kopczynska M, Ufnal M. TMA (trimethylamine), but not its oxide TMAO (trimethylamine-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome. Cardiovasc Res. 2019;115:1948&#x02013;9.<pub-id pub-id-type="pmid">31504256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Restini</surname><given-names>CBA</given-names></name><name><surname>Fink</surname><given-names>GD</given-names></name><name><surname>Watts</surname><given-names>SW</given-names></name></person-group><article-title>Vascular reactivity stimulated by TMA and TMAO: Are perivascular adipose tissue and endothelium involved?</article-title><source>Pharmacological Res</source><year>2021</year><volume>163</volume><fpage>105273</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.105273</pub-id></element-citation><mixed-citation id="mc-CR145" publication-type="journal">Restini CBA, Fink GD, Watts SW. Vascular reactivity stimulated by TMA and TMAO: Are perivascular adipose tissue and endothelium involved?. Pharmacological Res. 2021;163:105273.</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>DM</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><name><surname>Che</surname><given-names>N</given-names></name><name><surname>Charugundla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis [S]</article-title><source>J lipid Res</source><year>2015</year><volume>56</volume><fpage>22</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1194/jlr.M051680</pub-id><pub-id pub-id-type="pmid">25378658</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Shih DM, Wang Z, Lee R, Meng Y, Che N, Charugundla S, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis [S]. J lipid Res. 2015;56:22&#x02013;37.<pub-id pub-id-type="pmid">25378658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>BM</given-names></name><name><surname>McManus</surname><given-names>SA</given-names></name><name><surname>Hughes</surname><given-names>WE</given-names></name><name><surname>Schmitz-Peiffer</surname><given-names>C</given-names></name></person-group><article-title>Flavin-containing monooxygenase 3 reduces endoplasmic reticulum stress in lipid-treated hepatocytes</article-title><source>Mol Endocrinol</source><year>2016</year><volume>30</volume><fpage>417</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1210/me.2015-1217</pub-id><pub-id pub-id-type="pmid">26886171</pub-id>
</element-citation><mixed-citation id="mc-CR147" publication-type="journal">Liao BM, McManus SA, Hughes WE, Schmitz-Peiffer C. Flavin-containing monooxygenase 3 reduces endoplasmic reticulum stress in lipid-treated hepatocytes. Mol Endocrinol. 2016;30:417&#x02013;28.<pub-id pub-id-type="pmid">26886171</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Warrier</surname><given-names>M</given-names></name><name><surname>Shih</surname><given-names>DM</given-names></name><name><surname>Burrows</surname><given-names>AC</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Gromovsky</surname><given-names>AD</given-names></name><name><surname>Brown</surname><given-names>AL</given-names></name><etal/></person-group><article-title>The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance</article-title><source>Cell Rep</source><year>2015</year><volume>10</volume><fpage>326</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.036</pub-id><pub-id pub-id-type="pmid">25600868</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL, et al. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Rep. 2015;10:326&#x02013;38.<pub-id pub-id-type="pmid">25600868</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>